



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N 15/54, 9/10, C12Q 1/68, C12N 5/10, A61K 38/45, C07K 16/40</p>	<p>(11) International Publication Number: WO 00/14251</p> <p>(43) International Publication Date: 16 March 2000 (16.03.00)</p>																																			
<p>(21) International Application Number: PCT/US99/20989</p> <p>(22) International Filing Date: 9 September 1999 (09.09.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td>09/150,657</td> <td>10 September 1998 (10.09.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>10 September 1998 (10.09.98)</td> <td>US</td> </tr> <tr> <td>09/186,779</td> <td>4 November 1998 (04.11.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>4 November 1998 (04.11.98)</td> <td>US</td> </tr> <tr> <td>60/133,642</td> <td>11 May 1999 (11.05.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td>US</td> <td>09/150,657 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>10 September 1998 (10.09.98)</td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> </tr> <tr> <td>Filed on</td> <td>10 September 1999 (10.09.99)</td> </tr> <tr> <td>US</td> <td>09/186,779 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>4 November 1998 (04.11.98)</td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> </tr> <tr> <td>Filed on</td> <td>4 November 1998 (04.11.98)</td> </tr> <tr> <td>US</td> <td>60/133,642 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>11 November 1998 (11.11.98)</td> </tr> </table>	09/150,657	10 September 1998 (10.09.98)	US	Not furnished	10 September 1998 (10.09.98)	US	09/186,779	4 November 1998 (04.11.98)	US	Not furnished	4 November 1998 (04.11.98)	US	60/133,642	11 May 1999 (11.05.99)	US	US	09/150,657 (CIP)	Filed on	10 September 1998 (10.09.98)	US	Not furnished (CIP)	Filed on	10 September 1999 (10.09.99)	US	09/186,779 (CIP)	Filed on	4 November 1998 (04.11.98)	US	Not furnished (CIP)	Filed on	4 November 1998 (04.11.98)	US	60/133,642 (CIP)	Filed on	11 November 1998 (11.11.98)	<p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
09/150,657	10 September 1998 (10.09.98)	US																																		
Not furnished	10 September 1998 (10.09.98)	US																																		
09/186,779	4 November 1998 (04.11.98)	US																																		
Not furnished	4 November 1998 (04.11.98)	US																																		
60/133,642	11 May 1999 (11.05.99)	US																																		
US	09/150,657 (CIP)																																			
Filed on	10 September 1998 (10.09.98)																																			
US	Not furnished (CIP)																																			
Filed on	10 September 1999 (10.09.99)																																			
US	09/186,779 (CIP)																																			
Filed on	4 November 1998 (04.11.98)																																			
US	Not furnished (CIP)																																			
Filed on	4 November 1998 (04.11.98)																																			
US	60/133,642 (CIP)																																			
Filed on	11 November 1998 (11.11.98)																																			
<p>(54) Title: HUMAN TRANSFERASE PROTEINS</p> <p>(57) Abstract</p> <p>The invention provides human transferase proteins (TRNSFS) and polynucleotides which identify and encode TRNSFS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of TRNSFS.</p>																																				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN TRANSFERASE PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human transferase proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, developmental disorders, gastrointestinal disorders, genetic disorders, immunological disorders, 5 neurological disorders, reproductive disorders, and smooth muscle disorders.

BACKGROUND OF THE INVENTION

Transferase Proteins

Transferases are enzymes that catalyze the transfer of molecular groups from a donor to 10 an acceptor molecule. The reaction may involve an oxidation, reduction, or cleavage of covalent bonds and is often specific to a substrate or to particular sites on a type of substrate. Transferase proteins participate in reactions essential to such functions as synthesis and degradation of cell components, and regulation of cell functions, including cell signaling, cell proliferation, inflammation, apoptosis, secretion and excretion. Transferases are involved in key steps in 15 disease processes involving these functions. These enzymes are frequently classified according to the type of group transferred. For example, methyl transferases transfer one-carbon methyl groups, amino transferases transfer nitrogenous amino groups, and similarly denominated enzymes transfer aldehyde or ketone, acyl, glycosyl, alkyl or aryl, isoprenyl, saccharyl, phosphorous-containing, sulfur-containing, or selenium-containing groups, as well as small 20 enzymatic groups such as Coenzyme A.

One example of a glycosyl transferase is O-linked N-acetylglucosamine (O-GlcNAc) transferase, an enzyme that catalyzes the reaction of monosaccharide N-acetylglucosamine linking to the hydroxyl group of a serine or threonine residue. O-GlcNAc and N-acetyl- β -D-glucosaminidase (O-GlcNAcase), regulate the attachment and removal, respectively, of O-GlcNAc 25 from proteins in a manner analogous to regulation of protein phosphorylation by kinases and phosphatases. O-GlcNAc transferase has been localized primarily in the nucleus and the cytosol of cells and has been shown to play a role in several cellular systems such as transcription, nuclear transport, and cytoskeletal organization. O-GlcNAc transferase is a heterodimer consisting of two catalytic 110-kDa (p110) subunits and one 78-kDa (p78) subunit. The gene encoding this enzyme 30 is highly conserved. The amino terminus of the p110 subunit has homology to the tetratricopeptide repeat (TPR) motif, while the carboxyl terminus has no significant homology

(Kreppel, L.K. et al. (1997) J. Biol. Chem. 272:9308-9315). Proteins containing the TPR motif interact through this TPR domain to form regulatory complexes. TPR motifs are believed to play a role in modulation of cellular processes such as cell cycle, transcription, and protein transport (Das, A.K. et al. (1998) EMBO J 17:1192-1199).

5 The enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is a purine salvage enzyme that catalyzes the conversion of hypoxanthine and guanine to their respective mononucleotides. HGPRT is ubiquitous, is known as a 'housekeeping' gene, and is frequently used as an internal control for reverse transcriptase polymerase chain reactions. There is a serine-tyrosine dipeptide that is conserved among all members of the HGPRT family and is essential for
10 the phosphoribosylation of purine bases (Jardim, A. and Ullman, B. (1997) J. Biol. Chem. 272:8967-8973). A partial deficiency of HGPRT can lead to overproduction of uric acid, causing a severe form of gout. An absence of HGPRT causes Lesch-Nyhan syndrome, characterized by hyperuricaemia, mental retardation, choreoathetosis, and compulsive self-mutilation (Sculley, D.G. et al. (1992) Hum Genet 90:195-207).

15 Polyprenyl transferases catalyze the addition of polyprenyl groups to molecules. For example, the enzyme 1,4-dihydroxy-2-napthoate octaprenyltransferase catalyzes the conversion of the soluble 1,4-dihydroxy-2-napthoic acid (DHNA) to the membrane-bound demethylmenaquinone by attaching a 40-C side chain to DHNA, a key step in the biosynthesis of menaquinone (vitamin K2). This octaprenyltransferase is a membrane protein in Escherichia coli
20 that is necessary for the synthesis of menaquinone (Suvarna, K. et al. (1998) J. Bacteriol. 180:2782-2787). Quinones, in many cases, take part in the oxidation-reduction cycles essential to living organisms (Morrison, R.T. and Boyd, R.N. (1987) Organic Chemistry, Allyn and Bacon, Inc., Newton, Massachusetts, pp. 1092-1093). Other octaprenyltransferases have been shown to allow the synthesis of quinones under anaerobic conditions and, therefore, may play a role in
25 anaerobic metabolism (Alexander, K. and Young, I.G. (1978) Biochemistry 17:4750-4755).

 The synthesis of 3'-phosphoadenosine-5'-phosphosulfate (PAPS) requires two enzymes, adenosine triphosphate (ATP) sulfurylase and adenosine 5'-phosphosulfate (APS) kinase. ATP sulfurylase catalyzes the formation of APS from ATP and free sulfate. APS kinase phosphorylates APS to produce PAPS, the sole source of donor sulfate in higher organisms. In bacteria, fungi,
30 yeast, and plants, these two enzymes are separate polypeptides. In animals, ATP sulfurylase and APS kinase are present in a single protein. The bifunctional enzyme found in mammals shows extensive homology to known sequences of both ATP sulfurylases and APS kinases. APS kinase peptide sequences are well conserved and contain an ATP-GTP binding motif (P-loop) flanked by cysteine residues and a PAPS-dependent enzyme motif. ATP sulfurylase peptide sequences have

a PP-motif found in ATP sulfurylases and PAPS reductases (Rosenthal, E. and Leustek, T. (1995) *Gene* 165:243-248; Li, H. et al. (1995) *J. Biol. Chem.* 270:29453-29459; Deyrup, A.T. et al. (1998) *J. Biol. Chem.* 273:9450-9456; Bork, P. and Koonin, E.V. (1994) *Proteins* 20:347-355).

The enzyme phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes the
 5 methylation of phosphatidylethanolamine. Hepatocytes in the liver synthesize
 phosphatidylcholine (PC) by stepwise methylation of phosphatidylethanolamine and have
 abundant activity for PEMT. Other cells and tissues express minimal activities for PEMT. All
 mammalian cells, including hepatocytes, synthesize PC from choline via the CDP-choline
 pathway. Evidence suggests that one function of hepatic PEMT is to maintain PC synthesis and
 10 generate choline when dietary supply of choline is insufficient, as occurs during pregnancy,
 lactation, or starvation (Walkey, C.J. et al. (1998) *J. Biol. Chem.* 273 :27043-27046). Forms of
 PEMT may also play a role in hepatocyte proliferation and liver cancer (Walkey, C.J. et al. (1999)
Biochim. Biophys. Acta 1436:405-412). In the brain, decreased PEMT activity has been
 associated with Alzheimer's disease (Guan, Z.Z. et al. (1999) *Neurochem. Int.* 34:41-47).

15 Sulfotransferase enzymes catalyze the transfer of sulfur-containing groups to molecules.
 For example, HNK-1 sulfotransferase (HNK-1ST) forms the HNK-1 carbohydrate epitope by
 adding a sulfate group to glycoproteins and glycolipids. The HNK-1 epitope was discovered by an
 antibody against human natural killer cells and is found in neural adhesion molecules, including
 N-CAM and myelin-associate glycoprotein. The HNK-1 carbohydrate epitope was recognized to
 20 have functional significance as an auto-antigen involved in peripheral demyelinating neuropathy.
 The HNK-1ST is a type II membrane protein with a consensus sequence shared by Golgi-
 associated sulfotransferases. The human and rat HNK-1STs share 90% homology in amino acid
 sequence. Human HNK-1ST was predominantly detected in fetal brain and in adult brain, testis,
 and ovary. (See Ong, E. et al. (1998) *J. Biol. Chem.* 273:5190-5195.)

25 Carnitine palmitoyltransferase I (CPT I) is an enzyme that catalyzes the transfer of fatty
 acyl groups from coenzyme A to carnitine, the rate-determining step in mitochondrial fatty acid β -
 oxidation (a major source of energy production in the cell). CPT I has two structural genes (α and
 β) that are differentially expressed in tissues that utilize fatty acids as fuel. The α structure is
 expressed most highly in the liver, pancreatic β cells, and heart. The β structural gene of CPT I is
 30 predominately expressed in skeletal muscle, adipose tissue, heart, and testis (Yu, G.S. et al. (1998)
J. Biol. Chem. 273:32901-32909). CPT I deficiency is a life-threatening disorder that appears to
 be treatable with medium-chain triglycerides. The disorder first presents, between 8 and 18
 months, with Reye syndrome-like episodes associated with fasting due to viral infection or
 diarrhea. Coma, seizures, hepatomegaly, and hypoketotic hypoglycemia characterize these

episodes. Persistent neurological defects are common (Online Mendelian Inheritance in Man entry #255120; ExPASy Enzyme:EC 2.3.1.21).

The enzyme glycine N-methyltransferase catalyzes the transfer of the methyl group from S-adenosylmethionine to glycine to form S-adenosylhomocysteine and sarcosine. Glycine N-methyltransferase is a tetramer of identical subunits, has a nucleotide binding region, and is localized in the liver. Amino acid sequence homology is found between glycine N-methyltransferases from rat, rabbit, pig, and human livers. Glycine N-methyltransferase can exist as a dimer which binds polycyclic aromatic hydrocarbons (PAHs) and acts as a transcriptional activator (Ogawa, H. et al. (1998) *Int. J. Biochem. Cell Biol.* 30:13-26; Bhat, R. and Bresnick, E. (1997) *J. Biol. Chem.* 272:21221-21226).

Myristoyl CoA:protein N-myristoyl-transferase

N-acylation with the 14-carbon fatty acid, myristate is found on the amino groups of N-terminal glycines of a number of proteins that are essential to normal cell functioning and/or are potential therapeutic targets of disease. Examples of such proteins include subunits of heterotrimeric G proteins, GTP-binding arf1, human immunodeficiency virus gag and nef proteins, myristoylated alanine-rich C kinase substrate (MARCKS), the protein phosphatase calcineurin B, the pp60^{src} protein tyrosine kinase, the retinal calcium-binding recoverin, the caveolae-associated endothelial nitric oxide synthase, the catalytic subunit of cAMP-dependent protein kinase, and mitochondria-associated cytochrome b5 reductase. (Glover, C.J. et al. (1997) *J. Biol. Chem.* 272:28680-28689.) N-myristoylated proteins are associated with a variety of organelles with the myristate moiety required for such diverse functions as specific protein-protein or protein-lipid interactions, ligand-induced protein conformational changes, and correct subcellular targeting.

Protein myristoylation occurs almost exclusively cotranslationally during protein synthesis of the first 100 amino acids. The reaction is catalyzed by the enzyme myristoyl CoA:protein N-myristoyl-transferase (NMT) 1 (EC 2.3.1.97). (Towler, D. A. et al. (1987) *Proc. Natl. Acad. Sci.* 84:2708-2712.) Immunofluorescence microscopy reveals NMT to be distributed uniformly throughout the cytoplasm of yeast and mammalian cells. This finding, plus evidence that N-myristoylation occurs on nascent polypeptides bound to free polyribosomes, establish that NMT is physically localized and functionally active in the cell cytoplasm. (Wilcox, C. et al. (1987) *Science* 238:1275-1278.)

Protein N-myristoylation appears to be a tightly regulated process involving i) the coordinated participation of several different enzymes/proteins, e.g. N-methionylaminopeptidase, fatty acid synthetase, long chain acyl-CoA synthetase, acyl-CoA-binding proteins; ii) access of NMT to pools of myristoyl-CoA substrate; and iii) N-myristoylation of nascent polypeptide

substrates during protein synthesis to avoid potential interfering reactions such as N-acetylation and polypeptide folding. The ability of NMT to function in regulated N-myristoylation has implied the existence of mechanisms designed to ensure targeting of NMT to the appropriate protein synthesis machinery. These mechanisms may involve interactions with other cooperating components that facilitate the recognition and efficient N-myristoylation of the rapidly growing polypeptide substrates. (Glover, et al. *supra*.) Protein N-myristoylation activity may be a chemotherapeutic target for cancer, infectious diseases, and immune disorders. Antagonists of NMT may reduce posttranslational myristoylation of oncoproteins and other growth-activating cellular proteins. (Felsted, R.L. et al., (1995) J. Natl. Cancer Inst. 87:1571-1573; Furuishi, K. et al., (1997) Biochem. Biophys. Res. Comm. 237:504-511.)

Mannose-1-phosphate guanyltransferase

Many secretory proteins and membrane proteins are glycosylated proteins that have covalently attached carbohydrate chains, or oligosaccharides. Some of these glycoproteins have only one or a few carbohydrate groups while others have numerous oligosaccharide side chains, which may be linear or branched. The sugar residues of many plasma membrane glycoproteins orient these proteins in membranes. Sugar residues of glycoproteins are hydrophilic and strongly prefer to be located near the aqueous or extracellular surface rather than the hydrocarbon core of the plasma membrane. Because there is a high energy barrier to the rotation of a glycoprotein from one side of the membrane to the other, the carbohydrate groups of membrane glycoproteins help to maintain the asymmetric character of biological membranes. One of the best-characterized glycoproteins is glycophorin, a protein found in the membrane of red blood cells. Many soluble glycoproteins are known as well, including carrier proteins, antibodies, and many of the proteins contained in lysosomes. Carbohydrate groups of plasma membrane glycoproteins play a major role in cell-cell recognition. Oligosaccharides are involved in many inflammatory processes and may also provide targets for tumor immunotherapy.

Glycoproteins are often linked to their oligosaccharides through asparagine (N) residues. These N-linked oligosaccharides are very diverse, but the many pathways by which they all form have a common first step. A 14 residue core oligosaccharide, containing two N-acetylglucosamine, nine mannose, and three glucose residues, is transferred from a dolichol phosphate donor molecule to certain N residues on the proteins (reviewed in Lehninger, A. L. et al. (1993) Principles of Biochemistry, Worth Publishers, New York, NY, pp. 931). Glycosylation is the most extensive of all post-translational modifications in proteins and is essential for the secretion, antigenicity, and clearance of glycoproteins.

A variety of enzymes which are involved in sugar metabolism participate directly or indirectly in glycosylation, such as certain pyrophosphorylases. ADP-glucose pyrophosphorylases play an important role in the biosynthesis of alpha 1,4-glucans (glycogen or starch) in bacteria and plants. Specifically, ADP-glucose pyrophosphorylases catalyze the synthesis of the activated glucosyl donor, ADP-glucose, from glucose-1-phosphate and ATP. ADP-glucose pyrophosphorylases are tetrameric, allosterically regulated enzymes. There are a number of conserved regions in the sequence of bacterial and plant ADP-glucose pyrophosphorylase subunits. Additionally, there are three regions which are considered signature patterns (ExPASy PROSITE database, documents PS00808-PS00810). The first two regions are N-terminal and have been proposed to be part of the allosteric and substrate-binding sites in the *Escherichia coli* enzyme. The third pattern corresponds to a conserved region in the central part of the enzymes.

In eukaryotic cells, mannose-1-phosphate guanylttransferase is involved in early steps of protein glycosylation. This enzyme participates in mannose metabolism, and its enzymatic products are channeled into glycoprotein synthesis. Mannose-1-phosphate guanylttransferase (MPG), also referred to as NDP-hexose pyrophosphorylase or GDP-mannose pyrophosphorylase B, catalyzes the conversion of GTP and α -D-mannose 1-phosphate into diphosphate and CDP-ethanolamine. This enzyme is very similar to CDP-glucose pyrophosphorylase and may be involved in the regulation of cell cycle progression. A cDNA coding for MPG1 was recently isolated from a *Trichoderma reesei* cDNA library (Kruszewska, J. S. et al. (1998) Curr. Genet. 33:445-500). The nucleotide sequence of the 1.6 kb cDNA revealed an ORF which encodes a protein of 364 amino acids. Sequence comparisons demonstrate that this protein shares 70% identity with the yeast *Saccharomyces cerevisiae* MPG1 gene and 75% identity with the *Schizosaccharomyces pombe* gene. MPGs are conserved among diverse organisms. For example, recent genome sequencing projects have identified MPG homologs in the plant *Arabidopsis thaliana* and the nematode *Caenorhabditis elegans* (SEQ ID NO:32 and SEQ ID NO:33, respectively).

Alterations in glycosylation are known to occur in a number of disorders and diseases such as carbohydrate-deficient glycoprotein syndromes (CDGSs). In the biochemical pathway upstream of MPG is an important enzyme called phosphomannomutase (PMM) which provides the mannose 1-phosphate required for the reaction catalyzed by MPG. PMM catalyzes the conversion of D-mannose 6-phosphate to D-mannose 1-phosphate and has been implicated in CDGSs. CDGSs are a group of hereditary multisystem disorders (Matthijs, G. et al. (1997) Nat. Genet. 16:88-92). The clinical phenotype of most CDGSs is dominated by severe psychomotor and mental retardation, as well as blood coagulation abnormalities as seen in thrombosis, bleeding,

or stroke-like episodes. The characteristic biochemical abnormality of CDGSs is the hypoglycosylation of glycoproteins. Depending on the type of CDGS, the carbohydrate side chains of glycoproteins are either truncated or completely missing from the protein core.

A new type of CDGS, designated as CDGS type 1B, has recently been described (Niehues, R. et al. (1998) Clin. Invest. 101:1414-1420). The clinical phenotype of this new disorder is fundamentally different from other types of CDGS in that no psychomotor or mental retardation is present. Instead, CDGS type 1B is a gastrointestinal disorder characterized by protein-losing enteropathy. Some patients who are affected with CDGS type 1B suffer from thrombosis and life-threatening bleeding. A deficiency of phosphomannose isomerase was identified as the most likely cause of this syndrome, and a therapy was developed in the form of oral administration of mannose (Niehues, supra). Mannose treatment can correct the clinical phenotype in CDGS type 1B. It is noteworthy that CDGS is the first inherited disorder in human metabolism that shows a decrease in available mannose. The above findings indicate that increasing blood mannose levels might correct some protein glycosylation deficiencies.

The discovery of new human transferase proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cancer, developmental disorders, gastrointestinal disorders, genetic disorders, immunological disorders, neurological disorders, reproductive disorders, and smooth muscle disorders.

SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, human transferase proteins, referred to collectively as "TRNSFS" and individually as "TRNSFS-1," "TRNSFS-2," "TRNSFS-3," "TRNSFS-4," "TRNSFS-5," "TRNSFS-6," "TRNSFS-7," "TRNSFS-8," "TRNSFS-9," "TRNSFS-10," "TRNSFS-11," "TRNSFS-12," "TRNSFS-13," "TRNSFS-14," and "TRNSFS-15." In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 (SEQ ID NO:1-15), and fragments thereof.

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-15 and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the

group consisting of SEQ ID NO:1-15 and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15 and fragments thereof.

5 Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino
10 acid sequence selected from the group consisting of SEQ ID NO:1-15 and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the
15 hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID
20 NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30 (SEQ ID NO:16-30), and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30 and fragments thereof. The invention also provides an isolated and purified
25 polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30 and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the
30 group consisting of SEQ ID NO:1-15 and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and

(b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-15 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

5 The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-15 and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of TRNSFS, the method comprising administering to a subject in
10 need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-15 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with
15 increased expression or activity of TRNSFS, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15 and fragments thereof.

BRIEF DESCRIPTION OF THE TABLES

20 Figures 1A and 1B show the amino acid sequence alignment between TRNSFS-1 (1632930; SEQ ID NO:1 and human myristoyl CoA:protein N-myristoyltransferase (GI 2443814; SEQ ID NO:31), produced using the multisequence alignment program of LASERGENE software (DNASTAR, Madison WI).

Figures 2A, 2B, 2C and 2D show the amino acid sequence alignments among TRNSFS-2
25 (2682663; SEQ ID NO:2), Arabidopsis thaliana MPG (GI 2642159; SEQ ID NO:32), and Caenorhabditis elegans MPG (GI 2804432; SEQ ID NO:33), produced using the multisequence alignment program of LASERGENE software (DNASTAR Inc, Madison WI).

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NO), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble
30 full-length sequences encoding TRNSFS.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods and algorithms used for identification of TRNSFS.

Table 3 shows useful fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases,
35 disorders, or conditions associated with these tissues; and the vector into which each cDNA was

cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding TRNSFS were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze TRNSFS, along with
5 applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods
10 described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for
15 example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention
20 belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be
25 construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"TRNSFS" refers to the amino acid sequences of substantially purified TRNSFS obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine,
30 equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to TRNSFS, increases or prolongs the duration of the effect of TRNSFS. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of TRNSFS.

An "allelic variant" is an alternative form of the gene encoding TRNSFS. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding TRNSFS include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as TRNSFS or a polypeptide with at least one functional characteristic of TRNSFS. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding TRNSFS, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding TRNSFS. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent TRNSFS. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of TRNSFS is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of TRNSFS which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of TRNSFS. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well

known in the art.

The term "antagonist" refers to a molecule which, when bound to TRNSFS, decreases the amount or the duration of the effect of the biological or immunological activity of TRNSFS.

Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules
5 which decrease the effect of TRNSFS.

The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind TRNSFS polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide
10 used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope)
15 that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

20 The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to
25 the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic TRNSFS, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with
30 specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that

total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding TRNSFS or fragments of TRNSFS may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding TRNSFS, by northern analysis is indicative of the presence of nucleic acids encoding TRNSFS in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding TRNSFS.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI) which creates alignments between two or more sequences according to methods selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) Parameters for each method may be the default parameters provided by MEGALIGN or may be specified by the user. The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) Methods Enzymol. 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements

required for stable mitotic chromosome segregation and maintenance.

The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

5 "Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one
10 nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively,
15 to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

20 The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of TRNSFS. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any
25 other biological, functional, or immunological properties of TRNSFS.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any
30 DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which comprise a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:16-30, for example, as distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:16-30 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:16-30 from related

polynucleotide sequences. A fragment of SEQ ID NO:16-30 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:16-30 and the region of SEQ ID NO:16-30 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. In some cases, a fragment, when
5 translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" and "operably linked" refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably
10 associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6
15 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which
20 comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic
25 acids encoding TRNSFS, or fragments thereof, or TRNSFS itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon
30 the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the
5 concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with
10 which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,
15 microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of
20 foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host
25 chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of TRNSFS polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine
30 with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to TRNSFS. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or
 5 lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between
 10 individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

THE INVENTION

15 The invention is based on the discovery of new human human transferase proteins (TRNSFS), the polynucleotides encoding TRNSFS, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, developmental disorders, gastrointestinal disorders, genetic disorders, immunological disorders, neurological disorders, reproductive disorders, and smooth muscle disorders.

20 Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding TRNSFS. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each TRNSFS were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their
 25 corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The clones in column 5 were used to assemble the consensus nucleotide sequence of each TRNSFS and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid
 30 residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods used to characterize each polypeptide through sequence homology and protein motifs. As shown in Figures 1A and 1B, SEQ ID NO:1 has chemical and

structural similarity with human myristoyl CoA:protein N-myristoyltransferase (GI 2443814; SEQ ID NO:31). In particular, SEQ ID NO:1 and human myristoyl CoA:protein N-myristoyltransferase share 74% identity, share two potential N-glycosylation sites, three potential casein kinase II phosphorylation sites, seven potential protein kinase C phosphorylation sites, the myristoyl CoA:protein N-myristoyltransferase signatures, and have similar isoelectric points, 7.7 and 8.2, respectively. SEQ ID NO:2 also has one potential bacterial hexapeptide-transferase signature from residue V₂₅₆ to V₂₈₄. This signature is conserved among a number of bacterial transferases which are believed to belong to a single family and are involved in the biosynthesis of glycolipids, polysaccharides, and other macromolecules. As shown in Figures 2A, 2B, 2C and 2D, SEQ ID NO:2 has chemical and structural similarity with Arabidopsis thaliana MPG (GI 2642159; SEQ ID NO:32), and Caenorhabditis elegans MPG (GI 2804432; SEQ ID NO:33). In particular, SEQ ID NO:2 and Arabidopsis thaliana MPG share 61% identity, and MPGh and Caenorhabditis elegans MPG share 63% identity. Note that the ADP-glucose pyrophosphorylase signature of MPGh is also conserved within both, Arabidopsis thaliana and Caenorhabditis elegans MPGs. In addition, the potential N-glycosylation site at residue N₃₂₂, the potential casein kinase II phosphorylation sites at residues S₇₈, T₁₃₆ and T₁₉₁, the potential tyrosine kinase phosphorylation site at residue Y₁₄₄, and the potential bacterial hexapeptide-transferase signature of SEQ ID NO:2 are conserved in both Arabidopsis thaliana and Caenorhabditis elegans MPGs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding TRNSFS. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:16-30 and to distinguish between SEQ ID NO:16-30 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express TRNSFS as a fraction of total tissues expressing TRNSFS. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing TRNSFS as a fraction of total tissues expressing TRNSFS. Column 5 lists the vectors used to subclone each cDNA library. Of particular note is the expression of SEQ ID NO:1 in reproductive, smooth muscle, and nervous tissue. Of particular note is the expression of SEQ ID NO:2 in reproductive and gastrointestinal tissue.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding TRNSFS were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the

cDNA libraries in column 2.

The invention also encompasses TRNSFS variants. A preferred TRNSFS variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the TRNSFS amino acid sequence, and which contains
5 at least one functional or structural characteristic of TRNSFS.

The invention also encompasses polynucleotides which encode TRNSFS. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:16-30, which encodes TRNSFS.

The invention also encompasses a variant of a polynucleotide sequence encoding
10 TRNSFS. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding TRNSFS. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:16-30 which has at least about 80%, more preferably at least
15 about 90%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:16-30. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of TRNSFS.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the
20 genetic code, a multitude of polynucleotide sequences encoding TRNSFS, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the
25 polynucleotide sequence of naturally occurring TRNSFS, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode TRNSFS and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring TRNSFS under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide
30 sequences encoding TRNSFS or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding TRNSFS and its derivatives without

altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode TRNSFS
5 and TRNSFS derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding TRNSFS or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of
10 hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:16-30 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium
15 citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and
20 most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a
25 more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

30 The washing steps which follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM

trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at
5 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS.

Additional variations on these conditions will be readily apparent to those skilled in the art.

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow
10 fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system
15 (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA), and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using the ABI 373 or 377 DNA sequencing systems (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g.,
20 Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding TRNSFS may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect
25 upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived
30 from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an

engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-306). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic
5 DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

10 When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

15 Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal
20 using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof
25 which encode TRNSFS may be cloned in recombinant DNA molecules that direct expression of TRNSFS, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express TRNSFS.

30 The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter TRNSFS-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example,

oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding TRNSFS may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 7:215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 7:225-232.) Alternatively, TRNSFS itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of TRNSFS, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active TRNSFS, the nucleotide sequences encoding TRNSFS or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding TRNSFS. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding TRNSFS. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding TRNSFS and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results

Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding TRNSFS and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding TRNSFS. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding TRNSFS. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding TRNSFS can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding TRNSFS into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of TRNSFS are needed, e.g. for the production of antibodies, vectors which direct high level expression of TRNSFS may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of TRNSFS. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel,

1995, supra; Grant et al. (1987) *Methods Enzymol.* 153:516-54; and Scorer, C. A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of TRNSFS. Transcription of sequences encoding TRNSFS may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding TRNSFS may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses TRNSFS in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of TRNSFS in cell lines is preferred. For example, sequences encoding TRNSFS can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These

include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding TRNSFS is inserted within a marker gene sequence, transformed cells containing sequences encoding TRNSFS can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding TRNSFS under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding TRNSFS and that express TRNSFS may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of TRNSFS using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on TRNSFS is preferred, but a competitive binding assay may be employed. These and other assays are well known in the

art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ).

5 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding TRNSFS include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding TRNSFS, or any fragments thereof, may be
10 cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter
15 molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding TRNSFS may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The
20 protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode TRNSFS may be designed to contain signal sequences which direct secretion of TRNSFS through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the
25 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for
30 post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas, VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding TRNSFS may be ligated to a heterologous sequence resulting in translation of

a fusion protein in any of the aforementioned host systems. For example, a chimeric TRNSFS protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of TRNSFS activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using
5 commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and
10 hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the TRNSFS encoding sequence and the heterologous protein sequence, so that TRNSFS may be cleaved away from the heterologous moiety following purification. Methods for fusion protein
15 expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled TRNSFS may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems
20 (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably ³⁵S-methionine.

Fragments of TRNSFS may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.)
25 Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of TRNSFS may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

30 Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of TRNSFS and human transferase proteins. In addition, the expression of TRNSFS is closely associated with cancerous and proliferating, gastrointestinal, inflamed, immunological, nervous, reproductive and smooth muscle tissue and fetal cell lines. Therefore, TRNSFS appears to play a role in cancer, developmental disorders, gastrointestinal disorders,

genetic disorders, immunological disorders, neurological disorders, reproductive disorders, and smooth muscle disorders. In the treatment of disorders associated with increased TRNSFS expression or activity, it is desirable to decrease the expression or activity of TRNSFS. In the treatment of disorders associated with decreased TRNSFS expression or activity, it is desirable to
5 increase the expression or activity of TRNSFS.

Therefore, in one embodiment, TRNSFS or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRNSFS. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in
10 particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal
15 dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma,
20 cataract, and sensorineural hearing loss; a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma,
25 biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, and acquired immunodeficiency syndrome (AIDS) enteropathy; a genetic disorder, such as Lesch-
30 Nyhan syndrome, mitochondrial carnitine palmitoyl transferase deficiency, carnitine deficiency, peroxisomal acyl-CoA oxidase deficiency, peroxisomal thiolase deficiency, peroxisomal bifunctional protein deficiency, mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency, mitochondrial medium-chain acyl-CoA dehydrogenase deficiency, mitochondrial short-chain acyl-CoA dehydrogenase deficiency, mitochondrial electron transport flavoprotein and

- electron transport flavoprotein:ubiquinone oxidoreductase deficiency, mitochondrial trifunctional protein deficiency, mitochondrial short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, adrenoleukodystrophy, Alport's syndrome, choroideremia, Duchenne and Becker muscular dystrophy, Down's syndrome, cystic fibrosis, chronic granulomatous disease, Gaucher's disease,
- 5 Huntington's chorea, Marfan's syndrome, muscular dystrophy, myotonic dystrophy, pycnodysostosis, Refsum's syndrome, retinoblastoma, sickle cell anemia, thalassemia, Werner syndrome, von Willebrand's disease, Wilms' tumor, and Zellweger syndrome; an immunological disorder, such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis,
- 10 amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis,
- 15 hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary
- 20 thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; a neurological disorder, such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders,
- 25 amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-
- 30 Strausler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorder of the central nervous system, cerebral palsy, a neuroskeletal disorder, an autonomic nervous system disorder, a cranial nerve disorder, a spinal cord disease, muscular dystrophy and other neuromuscular

disorder, a peripheral nervous system disorder, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathy; myasthenia gravis, periodic paralysis; a mental disorder including mood, anxiety, and schizophrenic disorders; seasonal affective disorder (SAD); akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid
5 psychoses, postherpetic neuralgia, and Tourette's disorder; a reproductive disorder, such as disorders of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis, disruptions of the estrous cycle, disruptions of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast,
10 fibrocystic breast disease, and galactorrhea, disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; and a smooth muscle disorder, such as angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and
15 pheochromocytoma, and myopathies including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia. A smooth muscle disorder is defined as any impairment or alteration in the normal action of smooth muscle and may include those disorders listed above. Smooth muscle includes, but is not limited to, that of the blood vessels, gastrointestinal tract, heart, and uterus.

20 In another embodiment, a vector capable of expressing TRNSFS or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRNSFS including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified TRNSFS in conjunction with a suitable pharmaceutical carrier may be administered to a
25 subject to treat or prevent a disorder associated with decreased expression or activity of TRNSFS including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of TRNSFS may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRNSFS including, but not limited to, those listed above.

30 In a further embodiment, an antagonist of TRNSFS may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRNSFS. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds TRNSFS may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express

TRNSFS.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding TRNSFS may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRNSFS including, but not limited to, those described above.

5 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment
10 or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of TRNSFS may be produced using methods which are generally known in the art. In particular, purified TRNSFS may be used to produce antibodies or to screen libraries of
15 pharmaceutical agents to identify those which specifically bind TRNSFS. Antibodies to TRNSFS may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

20 For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with TRNSFS or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such
25 as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to TRNSFS have an amino acid sequence consisting of at least about 5 amino acids, and, more
30 preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of TRNSFS amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to TRNSFS may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce TRNSFS-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) *Proc. Natl. Acad. Sci.* 88:10134-10137.)

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86: 3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for TRNSFS may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between TRNSFS and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering TRNSFS epitopes is preferred, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for TRNSFS. Affinity is expressed as

an association constant, K_a , which is defined as the molar concentration of TRNSFS-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple TRNSFS epitopes, represents the average affinity, or
5 avidity, of the antibodies for TRNSFS. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular TRNSFS epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the TRNSFS-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7
10 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of TRNSFS, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

15 The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of TRNSFS-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity,
20 and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, *supra*, and Coligan et al. *supra*.)

In another embodiment of the invention, the polynucleotides encoding TRNSFS, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding TRNSFS may be used in situations in which it would
25 be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding TRNSFS. Thus, complementary molecules or fragments may be used to modulate TRNSFS activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or
30 control regions of sequences encoding TRNSFS.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the

polynucleotides encoding TRNSFS. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding TRNSFS can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding TRNSFS. Such constructs may be used to introduce untranslatable sense or antisense sequences
5 into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing
10 complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding TRNSFS. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open
15 sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to
20 ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently
25 catalyze endonucleolytic cleavage of sequences encoding TRNSFS.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may
30 be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These

include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding TRNSFS. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of TRNSFS, antibodies to TRNSFS, and mimetics, agonists, antagonists, or inhibitors of TRNSFS. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial,

intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which
5 facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral
10 administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after
15 grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired,
20 disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or
25 solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or
30 starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution,

Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include 5 fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be 10 permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many 15 acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to 20 use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of TRNSFS, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions 25 wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or 30 pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example TRNSFS or fragments thereof, antibodies of TRNSFS, and agonists, antagonists or inhibitors of

TRNSFS, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

25 DIAGNOSTICS

In another embodiment, antibodies which specifically bind TRNSFS may be used for the diagnosis of disorders characterized by expression of TRNSFS, or in assays to monitor patients being treated with TRNSFS or agonists, antagonists, or inhibitors of TRNSFS. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for TRNSFS include methods which utilize the antibody and a label to detect TRNSFS in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring TRNSFS, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of TRNSFS expression. Normal or standard values for TRNSFS expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with
5 antibody to TRNSFS under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of TRNSFS expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

10 In another embodiment of the invention, the polynucleotides encoding TRNSFS may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of TRNSFS may be correlated with disease. The diagnostic assay may be used to determine absence,
15 presence, and excess expression of TRNSFS, and to monitor regulation of TRNSFS levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding TRNSFS or closely related molecules may be used to identify nucleic acid sequences which encode TRNSFS. The specificity
20 of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding TRNSFS, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably
25 have at least 50% sequence identity to any of the TRNSFS encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:16-30 or from genomic sequences including promoters, enhancers, and introns of the TRNSFS gene.

Means for producing specific hybridization probes for DNAs encoding TRNSFS include
30 the cloning of polynucleotide sequences encoding TRNSFS or TRNSFS derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by

enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding TRNSFS may be used for the diagnosis of disorders associated with expression of TRNSFS. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, 5 teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, 10 achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's 15 chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal 20 tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, and 25 acquired immunodeficiency syndrome (AIDS) enteropathy; a genetic disorder, such as Lesch-Nyhan syndrome, mitochondrial carnitine palmitoyl transferase deficiency, carnitine deficiency, peroxisomal acyl-CoA oxidase deficiency, peroxisomal thiolase deficiency, peroxisomal bifunctional protein deficiency, mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency, mitochondrial medium-chain acyl-CoA dehydrogenase deficiency, mitochondrial 30 short-chain acyl-CoA dehydrogenase deficiency, mitochondrial electron transport flavoprotein and electron transport flavoprotein:ubiquinone oxidoreductase deficiency, mitochondrial trifunctional protein deficiency, mitochondrial short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, adrenoleukodystrophy, Alport's syndrome, choroideremia, Duchenne and Becker muscular dystrophy, Down's syndrome, cystic fibrosis, chronic granulomatous disease, Gaucher's disease,

Huntington's chorea, Marfan's syndrome, muscular dystrophy, myotonic dystrophy, pycnodysostosis, Refsum's syndrome, retinoblastoma, sickle cell anemia, thalassemia, Werner syndrome, von Willebrand's disease, Wilms' tumor, and Zellweger syndrome; an immunological disorder, such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS),

5 Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves'

10 disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's

15 syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; a neurological disorder, such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease,

20 Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system

25 disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorder of the central nervous system, cerebral palsy, a neuroskeletal disorder, an autonomic nervous system disorder, a

30 cranial nerve disorder, a spinal cord disease, muscular dystrophy and other neuromuscular disorder, a peripheral nervous system disorder, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathy; myasthenia gravis, periodic paralysis; a mental disorder including mood, anxiety, and schizophrenic disorders; seasonal affective disorder (SAD); akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid

psychoses, postherpetic neuralgia, and Tourette's disorder; a reproductive disorder, such as disorders of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis, disruptions of the estrous cycle, disruptions of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine
5 fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea, disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; and a smooth muscle disorder, such as angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock,
10 Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma, and myopathies including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia. The polynucleotide sequences encoding TRNSFS may be used in Southern or Northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and
15 multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered TRNSFS expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding TRNSFS may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The
20 nucleotide sequences encoding TRNSFS may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide
25 sequences encoding TRNSFS in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of TRNSFS, a normal or standard profile for expression is established. This may be accomplished by
30 combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding TRNSFS, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with

values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding TRNSFS may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding TRNSFS, or a fragment of a polynucleotide complementary to the polynucleotide encoding TRNSFS, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of TRNSFS include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See,

e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

5 In another embodiment of the invention, nucleic acid sequences encoding TRNSFS may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial
10 P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in
15 Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding TRNSFS on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene
20 sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human
25 chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for
30 further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, TRNSFS, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a

variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between TRNSFS and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of
5 compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with TRNSFS, or fragments thereof, and washed. Bound TRNSFS is then detected by methods well known in the art. Purified TRNSFS can also be coated directly onto plates for use in the aforementioned drug
10 screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding TRNSFS specifically compete with a test compound for binding TRNSFS. In this manner, antibodies can be used to detect the presence of any peptide
15 which shares one or more antigenic determinants with TRNSFS.

In additional embodiments, the nucleotide sequences which encode TRNSFS may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

20 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below,
25 in particular U.S. Ser. No. [Attorney Docket No: PF-0592 P, filed September 10, 1998], U.S. Ser. No. [Attorney Docket No: PF-0624 P, filed November 4, 1998], and U.S. Ser. No. 60/133,642, are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

30 RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated

from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8, QIAWELL 8 Plus, QIAWELL 8 Ultra plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified

fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cyclor or the PTC-200 thermal cyclor (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready
10 reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were
15 identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides
20 applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher
25 the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent
30 identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases; using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian,

vertebrate, and eukaryote databases, and BLOCKS to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length
 5 polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families.
 10 (See, e.g., Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:16-30. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

15 IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

20 Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$25 \quad \frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar
 30 molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding TRNSFS occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular,

dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, fetal, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of TRNSFS Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:16 and of SEQ ID NO:18-30 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture

was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:16 and of SEQ ID NO:18-30 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

The full length nucleic acid sequence of SEQ ID NO: 17 was produced by extension of an appropriate fragment of the full length molecule, using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO 4.06 software (National Biosciences, Plymouth, MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer

dimerizations was avoided.

Selected human cDNA libraries (Life Technologies) were used to extend the sequence.

If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

- 5 High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin-Elmer Corp., Norwalk, CT) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the PTC-200 thermal cycler (MJ Research, Inc., Watertown, MA), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

10	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
15	Step 6	68° C for 7 min
	Step 7	Repeat steps 4 through 6 for an additional 15 cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
20	Step 11	Repeat steps 8 through 10 for an additional 12 cycles
	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

- A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low
 25 concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQUICK DNA gel purification kit (Qiagen, Inc.), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

- After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l
 30 T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium. (See, e.g., Sambrook, *supra*, Appendix A, p. 2.) After incubation for one hour at 37°C, the *E. coli* mixture was plated on Luria Bertani (LB) agar (See, e.g., Sambrook, *supra*,
 35 Appendix A, p. 1) containing carbenicillin (2x carb). The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5 μ l from each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

5	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
	Step 4	72° C for 90 sec
	Step 5	Repeat steps 2 through 4 for an additional 29 cycles
10	Step 6	72° C for 180 sec
	Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NO:17 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:16-30 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of $[\gamma\text{-}^{32}\text{P}]$ adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography and compared.

VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array

elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements.

- 5 After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may
10 comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g.,
15 UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

VIII. Complementary Polynucleotides

- 20 Sequences complementary to the TRNSFS-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring TRNSFS. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of
25 TRNSFS. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the TRNSFS-encoding transcript.

IX. Expression of TRNSFS

- 30 Expression and purification of TRNSFS is achieved using bacterial or virus-based expression systems. For expression of TRNSFS in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac*

operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express TRNSFS upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of TRNSFS in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding TRNSFS by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, TRNSFS is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from TRNSFS at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified TRNSFS obtained by these methods can be used directly in the following activity assay.

25 X. Demonstration of TRNSFS Activity

TRNSFS activity is determined by measuring the transfer of a radiolabeled molecular group from a donor to an acceptor molecule in the presence of TRNSFS. For example, HNK sulfotransferase activity is determined in a reaction mixture that contains 0.02 mM [³⁵S]PAPS, 25 µl of IgG bead-bound enzyme suspension, 0.1 mM acceptor oligosaccharides or 0.0265 mM acceptor glycolipids in 100 mM TRIS-HCl, pH 7.2, 0.1% Triton X-100, 10 mM MnCl₂, and 2.5 mM ATP. The mixture is incubated for two hours at 37°C. The reaction products are adjusted to 0.25 M ammonium formate, pH 4.0, and separated on a C18 reverse phase chromatography column. The column is washed and the products are eluted with 70% methanol. The radioactivity recovered in the acceptor molecule is measured using a liquid scintillation counter and is

proportional to the activity of HNK sulfotransferase in the assay.

Alternatively, myristoyl CoA:protein N-myristoyltransferase activity is demonstrated as the ability of TRNSFS to myristoylate a synthetic peptide substrate using the methods known in the art. (Giang, D.K. and Cravatt, B.F. (1998) J. Biol. Chem. 273:6595-6598; and Towler and Glaser (1986) Proc. Natl. Acad. Sci., 83:2812-2816.) [³H]Myristoyl-CoA (0.75 μ Ci; 52 Ci/mmol; 5 0.3 μ M; Amersham Pharmacia Biotech) is added to a mixture of COS-7 total cell protein (7.5 μ g) and peptide substrate (200 μ M; Towler and Glaser, supra) in a reaction buffer of 30 mM tris-HCl, pH 7.5, with 0.5 mM EDTA, 0.5 mM EGTA, 1.0% (v/v) Triton X-100, and 4.5 mM β -mercaptoethanol (total reaction volume of 50 μ l). The reaction is allowed to proceed for 10 min at 10 25 °C, then quenched with 50 μ l of methanol followed by 5 μ l of 100% trichloroacetic acid, placed on ice for 10 min, and spun at 10,000 x g for 5 min. Aliquots (25 μ l) of the supernatant are analyzed by reverse-phase high pressure liquid chromatography. A myristoylated peptide is synthesized as described (Towler and Glaser, supra) and used as a standard to define the elution times for myristoylated peptide products. Column fractions (1 ml) are collected and counted by 15 scintillation counting. In all cases, control reactions without peptide are also analyzed and subtracted from reactions with peptide to provide myristoyl-transferase reaction rates. Initial rates are determined from reactions in which less than 20% myristoylated product is formed. Myristoyltransferase reaction rate is proportional to the amount of TRNSFS present in the sample.

Alternatively, mannose-1-phosphate guanylttransferase activity is determined by 20 combining TRNSFS with its substrates GTP and α -D-mannose-1-phosphate at stoichiometric quantities under buffered conditions. At appropriate time points the products, CDP-ethanolamine and diphosphate are measured with chromatographic methods, whereby the reaction products are separated from the substrates. Under the standardized conditions of the assay, the amounts of CDP-ethanolamine and diphosphate produced are directly proportional to the activity of TRNSFS 25 in biological samples.

XI. Functional Assays

TRNSFS function is assessed by expressing the sequences encoding TRNSFS at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA 30 expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression

of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify
5 transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation
10 of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

15 The influence of TRNSFS on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding TRNSFS and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against
20 CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding TRNSFS and other genes of interest can be analyzed by Northern analysis or microarray techniques.

XII. Production of TRNSFS Specific Antibodies

TRNSFS substantially purified using polyacrylamide gel electrophoresis (PAGE; see,
25 e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the TRNSFS amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the
30 art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase

immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

5 **XIII. Purification of Naturally Occurring TRNSFS Using Specific Antibodies**

Naturally occurring or recombinant TRNSFS is substantially purified by immunoaffinity chromatography using antibodies specific for TRNSFS. An immunoaffinity column is constructed by covalently coupling anti-TRNSFS antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is
10 blocked and washed according to the manufacturer's instructions.

Media containing TRNSFS are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of TRNSFS (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/TRNSFS binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope,
15 such as urea or thiocyanate ion), and TRNSFS is collected.

XIV. Identification of Molecules Which Interact with TRNSFS

TRNSFS, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled TRNSFS, washed, and any
20 wells with labeled TRNSFS complex are assayed. Data obtained using different concentrations of TRNSFS are used to calculate values for the number, affinity, and association of TRNSFS with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of
25 the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

TABLE 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	16	1632930	COLNNOT19	1632930H1, 1632930T6.comp, and 1632930F6 (COLNNOT19), 2616972T6.comp (GBLANOT01), 1001793H1 (BRSTNOT03), 1327272H1 (BLADNOT04), 2535979H1 (BRAINOT18), 2779012T6.comp (OVARUT03)
2	17	2682663	SINIUCT01	2682663H1 (SINIUCT01), 2483825H1 (SMCANOT01), 785487R1 (PROSNOT05), 2643432F6 (LUNGUT08), 1214388H1 (BRSTTUT01), 2122443T6 (BRSTNOT07), 227895R6 (PROSNON01)
3	18	1265094	SYNORAT05	266269H1 (INT2NOT01), 605479R6 and 605479T6 (BRSTTUT01), 870033R6 (LUNGAST01), 928166R6 (BRAINOT04), 1265094H1 (SYNORAT05), 1914656H1 (PROSTUT04), 2737452H1 (OVARNOT09), 3351376H1 (PROSNOT28), 4998035H1 (MYEPTXT02), 5121429H1 (SMCBUNT01)
4	19	1404963	LATRTUT02	1404963H1 and 1404963T6 (LATRTUT02), 1742179T6 (HIPONON01), 2055278X19R1 (BEPINOT01), SBMAA0202IF1, SBMAA03096F1, SBMAA01345F1
5	20	1405058	LATRTUT02	154037H1 (THIPLB02), 1405058F6, 1405058H1, and 1405058T6 (LATRTUT02), 2371445F6 (ADRENUT07), 3235888F7 (COLNUCT03), 3674493H1 (PLACNOT07), 4985152H1 (LIVRTUT10)
6	21	1420940	KIDNNOT09	493640X19 (HINT2NOT01), 983695H1 (TONGTUT01), 1361219F6, 1361219X11, 1361219X13, and 1362434X11 (LUNGNOT12), 1420940H1 (KIDNNOT09), 1499443T6 (SINTBST01), 3655410F6 (ENDINOT02)
7	22	1784742	BRAINOT10	1286822H1 (BRAINOT11), 1784742H1 (BRAINOT10), 3243626H1 and 3244456F6 (BRAINOT19), 5013854F6 (BRAXNOT03)
8	23	1967138	BRSTNOT04	1513726T6 (PANCUTUT01), 1967138H1 (BRSTNOT04), SAEA03142R1, SAEA01673F1
9	24	2124351	BRSTNOT07	288743F1 (EOSHET02), 582937H1 (PROSNOT02), 890499R1 (STOMTUT01), 1380837F1 (BRAITUT08), 1444442F1 (THYRNUT03), 2124351H1 (BRSTNOT07), 2159702F6 (ENDCNOT02)
10	25	2153162	BRAINOT09	269898X29R1, 4958807F1 and 4958807R1 (HINT2NOT01), 1450490F1 (PENITUT01), 2153162H1, 2153162X14F1, 2153162X22F1, 2153162X40F1, and 2153162X46F1 (BRAINOT09), 3114632H1 (BRSTNOT17)
11	26	2617407	GBLANOT01	2039925T6 (HIPONON02), 2617407F6 and 2617407H1 (GBLANOT01), 2620445R6 (KERANOT02), SBGA01193F1, SBGA05513F1, SBGA02306F1, SBGA03105F1
12	27	2963717	SCORNOT04	1627889X24F1 (COLNPOT01), 2963717H1 and 2963717T6 (SCORNOT04), SBZA04180V1, SBZA00122V1, SBZA04721V1, SBZA00694V1
13	28	3360857	PROSTUT16	538662R6 (LNODNOT02), 830729R1 and 830729T1 (PROSTUT04), 3360857H1 (PROSTUT16), 5069726H1 (PANCNOT23)

TABLE 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
14	29	3449671	UTRSNON03	1418639T1 (KIDNNOT09), 1626239F6 (COLNPOT01), 1726392T6 (PROSNOT14), 2643253F6 (LUNGTUT08), 3049827F6 (LUNGNOT25), 3449671H1 (UTRSNON03), SBHA03052F1, SBHA03662F1, SBHA02654F1
15	30	5497787	BRABDIR01	358882R6 (SYNORAB01), 773882R6 (COLNNOT05), 5497787H1 (BRABDIR01), 5673443H1 (293TF2T01)

TABLE 2

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous Sequences	Analytical Methods
1	498	T64 S68 S166 S350 T462 T488 S220 S240 S258 T270 T295 T325 S350 S417 S490	N319 N460	Myristoyl-CoA protein N-myristoyltransferase: E246 - K254 K468 - G474 Myristoyl-CoA protein N-myristoyltransferase: E150 - I228 S240 - A285 G286 - F362 L436 - T488	Myristoyl CoA:protein N-myristoyltransferase (g2443814) [Homo sapiens]	BLAST, Motifs, BLOCKS
2	360	T290 S78 T136 T191 S301 S348 S352 T21 T153 S168 S235 S259 Y144	N265 N271 N322	Bacterial hexapeptide-transferase: V256 - V284 Putative ADP-glucose pyrophosphorylase: V7 - A44 V106 - Y144	Mannose-1-phosphate guanylyltransferase (g2642159) [Arabidopsis thaliana] Mannose-1-phosphate guanylyltransferase (g2804432) [Caenorhabditis elegans] O-linked GlcNAc transferase [Methanobacterium thermoautotrophicum] (g2621120)	BLAST, Motifs, BLOCKS
3	519	S403 T248 T349 S409 S508 S18 T452	N408	TPR Domains: Y171 - P199 L205 - P223 W273 - P301		BLAST, PFAM, Motifs
4	225	S176 S4 S117 S155 S96 S101 S111 T146 T149 T175	N91	Purine/pyrimidine phosphoribosyl-transferase Domain: Y35 - V225	hypoxanthine (guanine) phosphoribosyl-transferase (g461344)	BLAST, PFAM, BLOCKS, Motifs
5	338	T103 T120 S239 T18 S41 T312	N232	Transmembrane Domain: G177 - A202	octaprenyltransferase (g4982095)	BLAST, HMM, Motifs
6	619	S92 T176 S180 T198 T250 T285 S308 T313 T394 T453 T527 T548 T430 Y439	N195 N298	ATP/GTP-binding site (P-loop): G49 - T56	ATP sulfurylase/APS kinase 2 [Homo sapiens] (g3342266)	BLAST, Motifs
7	284	S4 T11 T157 S174 T205 S260 S104 S148 S153 Y172		Sulfotransferase Protein Domain: H23 - K272	Sulfotransferase-like protein (g1173670)	BLAST, PFAM, Motifs, BLOCKS

TABLE 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous Sequences	Analytical Methods
8	205	S49 T45 S201		Transmembrane Domain: L105 - L124 L169 - Y185	phosphatidylethanol-amine N-methyl-transferase [Rattus norvegicus] (g310195)	BLAST, HMM, Motifs
9	414	T88 T239 S64 S96 S107 S257 S287 T344 S374 S375 S100 T312 S367	N134 N209 N280 N370	Signal Peptide: M1 - A31 Transmembrane Domain: L9 - D27	HNK-1 sulfoltransferase [Rattus norvegicus] (g2660716)	BLAST, SPScan, HMM, Motifs
10	660	S20 S93 T118 S153 T176 S233 S247 S248 S270 S280 T285 T433 S550 T24 T61 S105 T188 S362 S535 S632 Y104		Transmembrane Domain: T41 - I58	N-acetylglucosaminyl-transferase I [Mus musculus] (g193527)	BLAST, HMM, Motifs
11	386	S121 S107 T217 S252 S364 T380 S35 S50 T81 T287 Y243	N30 N308 N329	Transmembrane Domain: M7 - F23	N-acetylglucosamine 6-O-sulfoltransferase (g4927116) [Mus musculus]	BLAST, HMM, Motifs
12	803	S739 S178 S195 T425 S471 T740 S775 T799 S38 S158 T182 S189 T313 S354 S396 T601 S734 S735 S744	N312	Acyltransferases ChoActase/COT/CPT family: S170 - A759	caritine palmitoyltransferase I [Rattus norvegicus] (g294521)	BLAST, PFAM, Motifs, BLOCKS, ProfileScan
13	295	T68 T83 S252 S88			glycine N-methyltransferase [Sus scrofa] (g217690)	BLAST, Motifs
14	575	S350 S40 S57 S210 T233 S273 S305 T494 T2 S3 S44 T284 T345 S371 S549	N110 N247 N250	Transmembrane Domain: T73 - R94	putative 3,4-dihydroxy-2-butanone kinase [Lycopersicon esculentum] (g1929056)	BLAST, HMM, Motifs
15	180	T15			O-GlcNAc transferase p110 subunit (g1931579)	BLAST, Motifs

TABLE 3

Nucleotide SEQ ID NO:	Useful Fragments of Nucleotide Sequence	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Fraction of Total)	Vector
16	170 - 214	Reproductive Nervous Smooth Muscle	Cancer Inflammation	pINCY
17	377 - 406	Reproductive Gastrointestinal	Cancer (0.530) Inflammation (0.280)	pINCY
18	711 - 770, 915 - 959 1503 - 1562	Reproductive (0.346) Nervous (0.212)	Cancer (0.519) Inflammation (0.173)	PSPORT1
19	649 - 693	Nervous (0.368) Cardiovascular (0.263) Gastrointestinal (0.105) Reproductive (0.105) Hematopoietic/Immune (0.105)	Cancer (0.789) Inflammation (0.105)	pINCY
20	833 - 892	Gastrointestinal (0.238) Hematopoietic/Immune (0.190) Cardiovascular (0.143)	Inflammation (0.429) Cancer (0.381) Cell proliferation (0.238)	pINCY
21	942 - 986	Cardiovascular (0.245) Gastrointestinal (0.170) Reproductive (0.170) Endocrine (0.151)	Cancer (0.396) Inflammation (0.302) Cell Proliferation (0.170)	pINCY
22	2 - 97	Nervous (0.882) Endocrine (0.059) Developmental (0.059)	Neurological (0.294) Inflammation (0.235) Cancer (0.176)	pINCY
23	3 - 62	Reproductive (0.390) Nervous (0.186) Gastrointestinal (0.119) Cardiovascular (0.119)	Cancer (0.559) Trauma (0.136) Inflammation (0.102)	PSPORT1
24	396 - 440 444 - 503	Reproductive (0.286) Nervous (0.265) Musculoskeletal (0.122) Hematopoietic/Immune (0.102)	Cancer (0.551) Inflammation (0.245) Cell proliferation (0.143)	pINCY
25	207 - 266 321 - 380	Reproductive (0.218) Nervous (0.188) Gastrointestinal (0.139)	Cancer (0.545) Inflammation (0.168)	pINCY
26	264 - 323 1272 - 1331	Dermatologic (0.500) Gastrointestinal (0.500)	Inflammation (0.500) Cell proliferation (0.500)	pINCY
27	310 - 370 505 - 547	Nervous (0.600) Gastrointestinal (0.133) Musculoskeletal (0.133) Reproductive (0.133)	Cancer (0.333) Trauma (0.200) Inflammation (0.133) Neurological (0.133)	pINCY
28	368 - 412	Gastrointestinal (0.417) Reproductive (0.417) Hematopoietic/Immune (0.167)	Cancer (0.333) Trauma (0.333) Inflammation (0.250)	pINCY
29	458 - 502, 1196 - 1381 1460 - 1513	Reproductive (0.279) Gastrointestinal (0.197) Nervous (0.131)	Cancer (0.492) Inflammation (0.164) Cell proliferation (0.164)	pINCY
30	236 - 280	Gastrointestinal (0.375) Endocrine (0.125) Hematopoietic/Immune (0.125) Musculoskeletal (0.125) Nervous (0.125)	Cancer (0.375) Inflammation (0.375) Neurological (0.125)	pINCY

TABLE 4

Polynucleotide SEQ ID NO:	Library	Library Description
16	COLNNOT19	The library was constructed using RNA isolated from the cecal tissue of an 18-year-old Caucasian female. The cecal tissue, along with the appendix and ileum tissues, were removed during bowel anastomosis. Pathology indicated Crohn's disease of the ileum, involving 15 cm of the small bowel.
17	SINIUCT01	The library was constructed using RNA isolated from ileum tissue removed from a 420-year-old Caucasian male during a total intra-abdominal colectomy and endoscopic jejunostomy. Pathology indicated that the disease was most severe in the colon with the distal end completely ulcerated. Patient history included tobacco abuse. Previous surgeries included polypectomy, colonoscopy, and spinal canal exploration. Family history included benign hypertension, cerebrovascular disease, atherosclerotic coronary artery disease, and type II diabetes.
18	SYNORAT05	The library was constructed using RNA isolated from the knee synovial tissue of a 62-year-old female with rheumatoid arthritis.
19	LATRTUT02	The library was constructed using RNA isolated from a myxoma removed from the left atrium of a 43-year-old Caucasian male during annuloplasty. Pathology indicated atrial myxoma. Patient history included pulmonary insufficiency, acute myocardial infarction, atherosclerotic coronary artery disease, hyperlipidemia, and tobacco use. Family history included benign hypertension, acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
20	LATRTUT02	The library was constructed using RNA isolated from a myxoma removed from the left atrium of a 43-year-old Caucasian male during annuloplasty. Pathology indicated atrial myxoma. Patient history included pulmonary insufficiency, acute myocardial infarction, atherosclerotic coronary artery disease, hyperlipidemia, and tobacco use. Family history included benign hypertension, acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
21	KIDNNOT09	The library was constructed using RNA isolated from the kidney tissue of a Caucasian male fetus, who died at 23 weeks' gestation.
22	BRAINOT10	The library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 74-year-old Caucasian male, who died from Alzheimer's disease.
23	BRSTNOT04	The library was constructed using RNA isolated from breast tissue removed from a 62-year-old East Indian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive grade 3 ductal carcinoma. Patient history included benign hypertension, hyperlipidemia, and hematuria. Family history included cerebrovascular and cardiovascular disease, hyperlipidemia, and liver cancer.
24	BRSTNOT07	The library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, cardiovascular disease, and type II diabetes.
25	BRAINOT09	The library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation.

TABLE 4 (cont.)

Polynucleotide SEQ ID NO:	Library	Library Description
26	GBLANOT01	The library was constructed using RNA isolated from diseased gallbladder tissue removed from a 53-year-old Caucasian female during a cholecystectomy. Pathology indicated mild chronic cholecystitis and cholelithiasis with approximately 150 mixed gallstones. Family history included benign hypertension.
27	SCORNOT04	The library was constructed using RNA isolated from cervical spinal cord tissue removed from a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.
28	PROSTUT16	The library was constructed using RNA isolated from prostate tumor tissue removed from a 55-year-old Caucasian male. Pathology indicated adenocarcinoma, Gleason grade 5+4. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Patient history included calculus of the kidney. Family history included lung cancer and breast cancer.
29	UTRSNON03	The normalized library was constructed from 6.4 million independent clones from a uterus library. RNA was isolated from uterine myometrial tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. Patient history included ventral hernia and a benign ovarian neoplasm. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9928).
30	BRABDIR01	The library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease, emphysema, and tobacco abuse.

TABLE 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less ESTs: fasta E value=1.0E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fasta E value= 1.0E-8 or less Full Length sequences: fasta score=100 or greater Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value= 1.0E-3 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res. 19:6563-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits, depending on individual protein families

TABLE 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Score= 4.0 or greater
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and fragments thereof.
2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, and

fragments thereof.

10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

5

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.

12. An expression vector comprising at least a fragment of the polynucleotide of
10 claim 3.

13. A host cell comprising the expression vector of claim 12.

14. A method for producing a polypeptide, the method comprising the steps of:

15 a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

15. A pharmaceutical composition comprising the polypeptide of claim 1 in
20 conjunction with a suitable pharmaceutical carrier.

16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.

25

18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased expression or activity of TRNSFS, the method comprising administering to a subject in need of
30 such treatment an effective amount of the pharmaceutical composition of claim 15.

20. A method for treating or preventing a disorder associated with increased expression or activity of TRNSFS, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

21. A polypeptide fragment of claim 1, wherein the fragment is an enzymatically active fragment.

1	M	A	E	D	S	E	A	A	S	Q	Q	S	L	E	L	D	D	Q	D	T	C	G	I	D	G	D	N	E	E	E	T	E	H	A	1632930 GI 2443814			
11	M	M	E	G	N	G	-	-	-	-	-	-	-	-	-	-	-	N	G	H	E	H	C	S	-	D	C	E	N	E	E	D	N	S	Y	N	GI 2443814	
36	K	G	-	-	S	P	G	G	Y	L	G	A	K	K	K	K	K	K	K	Q	K	R	K	K	E	K	P	N	S	G	G	T	K	S	D	S	1632930 GI 2443814	
25	R	G	G	L	S	P	A	N	D	T	G	A	K	K	K	K	K	K	Q	K	K	E	K	-	-	-	-	-	G	S	E	T	D	S			GI 2443814	
69	A	S	D	S	Q	E	I	K	I	Q	Q	P	S	K	N	P	S	V	P	M	Q	K	L	Q	D	I	Q	R	A	M	E	L	L	S	A	1632930 GI 2443814		
56	A	Q	D	-	-	-	-	-	-	-	Q	P	V	K	M	N	S	L	P	A	E	R	I	Q	E	I	Q	K	A	I	E	L	F	S	V			GI 2443814
104	C	Q	G	P	A	R	N	I	D	E	A	A	K	H	R	Y	Q	F	W	D	T	Q	P	V	P	K	L	D	E	V	I	T	S	H	G	1632930 GI 2443814		
84	G	Q	G	P	A	K	T	M	E	E	A	S	K	R	S	Y	Q	F	W	D	T	Q	P	V	P	K	L	G	E	V	V	N	T	H	G			GI 2443814
139	A	I	E	P	D	K	V	N	V	R	Q	E	P	Y	S	L	P	Q	G	F	M	W	D	T	L	D	L	S	D	A	E	V	L	K	E	1632930 GI 2443814		
119	P	V	E	P	D	K	D	N	I	R	Q	E	P	Y	T	L	P	Q	G	F	T	W	D	A	L	D	L	G	D	R	G	V	L	K	E			GI 2443814
174	L	Y	T	L	L	N	E	N	Y	V	E	D	D	D	N	M	F	R	F	D	Y	S	P	E	F	L	L	W	A	L	R	P	P	G	W	1632930 GI 2443814		
154	L	Y	T	L	L	N	E	N	Y	V	E	D	D	D	N	M	F	R	F	D	Y	S	P	E	F	L	L	W	A	L	R	P	P	G	W			GI 2443814
209	L	L	Q	W	H	C	G	V	R	V	S	S	N	K	K	L	V	G	F	I	S	A	I	P	A	N	I	R	I	Y	D	S	V	K	K	1632930 GI 2443814		
189	L	P	Q	W	H	C	G	V	R	V	S	S	R	K	L	V	G	F	I	S	A	I	P	A	N	I	H	I	Y	D	T	E	K	K			GI 2443814	
244	M	V	E	I	N	F	L	C	V	H	K	K	L	R	S	K	R	V	A	P	V	L	I	R	E	I	T	R	R	V	N	L	E	G	I	1632930 GI 2443814		
224	M	V	E	I	N	F	L	C	V	H	K	K	L	R	S	K	R	V	A	P	V	L	I	R	E	I	T	R	R	V	H	L	E	G	I			GI 2443814

FIGURE 1A

279	F	Q	A	V	Y	T	A	G	V	V	L	P	K	P	I	A	T	C	R	Y	W	H	R	S	L	N	P	R	K	L	V	E	V	K	F	1632930	GI 2443814
259	F	Q	A	V	Y	T	A	G	V	V	L	P	K	P	V	G	T	C	R	Y	W	H	R	S	L	N	P	R	K	L	I	E	V	K	F	1632930	GI 2443814
314	S	H	L	S	R	N	M	T	L	Q	R	T	M	K	L	Y	R	L	P	D	V	T	K	T	S	G	L	R	P	M	E	P	K	D	I	1632930	GI 2443814
294	S	H	L	S	R	N	M	T	M	Q	R	T	M	K	L	Y	R	L	P	E	T	P	K	T	A	G	L	R	P	M	E	T	K	D	I	1632930	GI 2443814
349	K	S	V	R	E	L	I	N	T	Y	L	K	Q	F	H	L	A	P	V	M	D	E	E	E	V	A	H	W	F	L	P	R	E	H	I	1632930	GI 2443814
329	P	V	V	H	Q	L	L	T	R	Y	L	K	Q	F	H	L	T	P	V	M	S	Q	E	E	V	E	H	W	F	Y	P	Q	E	N	I	1632930	GI 2443814
384	I	D	T	F	V	V	E	S	P	N	G	K	L	T	D	F	L	S	F	Y	T	L	P	S	T	V	M	H	H	P	A	H	K	S	L	1632930	GI 2443814
364	I	D	T	F	V	V	E	N	A	N	G	E	V	T	D	F	L	S	F	Y	T	L	P	S	T	I	M	N	H	P	T	H	K	S	L	1632930	GI 2443814
419	K	A	A	Y	S	F	Y	N	I	H	T	E	T	P	L	L	D	L	M	S	D	A	L	I	L	A	K	S	K	G	F	D	V	F	N	1632930	GI 2443814
399	K	A	A	Y	S	F	Y	N	V	H	T	Q	T	P	L	L	D	L	M	S	D	A	L	V	L	A	K	M	K	G	F	D	V	F	N	1632930	GI 2443814
454	A	L	D	L	M	E	N	K	T	F	L	E	K	L	K	F	G	I	G	D	G	N	L	Q	Y	Y	L	Y	N	W	R	C	P	G	T	1632930	GI 2443814
434	A	L	D	L	M	E	N	K	T	F	L	E	K	L	K	F	G	I	G	D	G	N	L	Q	Y	Y	L	Y	N	W	K	C	P	S	M	1632930	GI 2443814
489	D	S	E	K	V	G	L	V	L	Q																									1632930	GI 2443814	
469	G	A	E	K	V	G	L	V	L	Q																									1632930	GI 2443814	

FIGURE 1B

1	M	-	-	-	-	-	-	-	-	K	A	L	I	L	V	G	G	Y	G	T	2682663
1	M	-	-	-	-	-	-	-	-	K	A	L	I	L	V	G	G	F	G	T	g2642159
1	M	V	V	S	P	L	P	S	M	K	A	L	I	L	V	G	G	Y	G	T	g2804432
13	R	L	R	P	L	T	L	S	T	P	K	P	L	V	D	F	C	N	K	P	2682663
13	R	L	R	P	L	T	L	S	F	P	K	P	L	V	D	F	A	N	K	P	g2642159
21	R	L	R	P	L	T	L	T	Q	P	K	P	L	V	E	F	A	N	K	P	g2804432
33	I	L	L	H	Q	V	E	A	L	A	A	A	G	V	D	H	V	I	L	A	2682663
33	M	I	L	H	Q	I	E	A	L	K	A	V	G	V	D	E	V	V	L	A	g2642159
41	M	M	L	H	Q	M	E	A	L	A	E	V	G	V	D	T	V	V	L	A	g2804432
53	V	S	Y	M	S	Q	V	L	E	K	E	M	K	A	Q	E	Q	R	L	G	2682663
53	I	N	Y	Q	P	E	V	M	L	N	F	L	K	D	F	E	T	K	L	E	g2642159
61	V	S	Y	R	A	E	Q	L	E	Q	E	M	T	V	H	A	D	R	L	G	g2804432
73	I	R	I	S	M	S	H	E	E	E	P	L	G	T	A	G	P	L	A	L	2682663
73	I	K	I	T	C	S	Q	E	T	E	P	L	G	T	A	G	P	L	A	L	g2642159
81	V	K	L	I	F	S	L	E	E	E	P	L	G	T	A	G	P	L	A	L	g2804432
93	A	R	-	D	L	L	S	E	T	A	D	P	F	F	V	L	N	S	D	V	2682663
93	A	R	D	K	L	L	D	G	S	G	E	P	F	F	V	L	N	S	D	V	g2642159
101	A	R	-	K	H	L	-	E	G	D	A	P	F	F	V	L	N	S	D	V	g2804432

FIGURE 2A

112	I	C	D	F	P	F	Q	A	M	V	Q	F	H	R	H	H	G	Q	E	G	2682663
113	I	S	E	Y	P	L	K	E	M	L	E	F	H	K	S	H	G	G	E	A	92642159
119	I	C	D	F	P	F	K	Q	M	V	E	F	H	K	N	H	G	K	E	G	92804432
132	S	I	L	V	T	K	V	E	E	P	S	K	Y	G	V	V	V	C	E	A	2682663
133	S	I	M	V	T	K	V	D	E	P	S	K	Y	G	V	V	V	M	E	E	92642159
139	T	I	A	V	T	K	V	E	E	P	S	K	Y	G	V	V	V	F	D	Q	92804432
152	D	T	G	R	I	H	R	F	V	E	K	P	Q	V	F	V	S	N	K	I	2682663
153	S	T	G	R	V	E	K	F	V	E	K	P	K	L	Y	V	G	N	K	I	92642159
159	D	K	G	K	I	D	D	F	V	E	K	P	Q	E	Y	V	G	N	K	I	92804432
172	N	A	G	M	Y	I	L	S	P	A	V	L	R	R	I	Q	L	Q	P	T	2682663
173	N	A	G	I	Y	L	L	N	P	S	V	L	D	K	I	E	L	R	P	T	92642159
179	N	A	G	L	Y	I	F	S	S	K	I	L	D	R	I	P	L	K	P	T	92804432
192	S	I	E	K	E	V	F	P	I	M	A	K	E	G	Q	L	Y	A	M	E	2682663
193	S	I	E	K	E	T	F	P	K	I	A	A	Q	Q	G	L	Y	A	M	V	92642159
199	S	I	E	K	E	I	F	P	E	M	A	F	S	G	N	L	Y	A	F	V	92804432
212	L	Q	G	F	W	M	D	I	G	Q	P	K	D	F	L	T	G	M	C	L	2682663
213	L	P	G	F	W	M	D	I	G	Q	P	R	D	Y	I	T	G	L	R	L	92642159
219	L	P	G	F	W	M	D	V	G	Q	P	K	D	F	L	K	G	M	S	L	92804432

FIGURE 2B

232	F	L	Q	S	L	R	Q	K	Q	P	E	R	L	C	S	G	P	G	I	V	2682663	
233	Y	L	D	S	L	R	K	K	S	P	A	K	L	T	S	G	P	H	I	V	g2642159	
239	F	L	N	H	C	H	T	T	K	S	D	K	L	E	T	G	S	N	I	H	g2804432	
252	-	-	-	-	-	-	-	G	N	V	L	V	D	P	S	A	R	I	G	Q	N	2682663
253	-	-	-	-	-	-	-	G	N	V	L	V	D	E	T	A	T	I	G	E	G	g2642159
259	P	T	A	T	I	R		G	N	V	M	V	D	P	S	A	T	V	G	E	N	g2804432
266	C	S	I	G	P	N	V	S	L	G	P	G	V	V	E	D	G	V	C			2682663
267	C	L	I	G	P	D	V	A	I	G	P	G	C	I	V	E	S	G	V	R		g2642159
279	C	V	I	G	P	D	V	V	I	G	P	R	V	K	I	E	G	G	V	R		g2804432
286	I	R	R	C	T	V	L	R	D	A	R	I	R	S	H	S	W	L	E	S		2682663
287	L	S	R	C	T	V	M	R	G	V	R	I	K	K	H	A	C	I	S	S		g2642159
299	I	L	H	S	T	I	L	S	D	S	S	I	G	N	Y	S	W	V	S	G		g2804432
306	C	I	V	G	W	R	C	R	V	G	Q	W	V	R	M	E	N	V	T	V		2682663
307	S	I	I	G	W	H	S	T	V	G	Q	W	A	R	I	E	N	M	T	I		g2642159
319	S	I	V	G	R	K	C	H	I	G	S	W	V	R	I	E	N	I	C	V		g2804432
326	L	G	E	D	V	I	V	N	D	E	L	Y	L	N	G	A	S	V	L	P		2682663
327	L	G	E	D	V	H	V	S	D	E	I	Y	S	N	G	G	V	V	L	P		g2642159
339	I	G	D	D	V	V	V	K	D	E	L	Y	L	N	G	A	S	V	L	P		g2804432

FIGURE 2C

2682663
g2642159
g280443

346	H	K	S	I	G	E	S	V	P	E	P	R	I	I	M
347	H	K	E	I	K	S	N	I	L	K	P	E	I	V	M
359	H	K	S	I	A	V	N	V	P	S	K	D	I	I	M

FIGURE 2D

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

TANG, Y. Tom

CORLEY, Neil C.

GUEGLER, Karl J.

BAUGHN, Mariah R.

LAL, Preeti

YUE, Henry

HILLMAN, Jennifer L.

AZIMZAI, Yalda

<120> HUMAN TRANSFERASE PROTEINS

<130> PF-0592 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/150,657; unassigned; 09/186,779; unassigned; 60/133,642

<151> 1998-09-10; 1998-09-10; 1998-11-04; 1998-11-04; 1999-05-11

<160> 33

<170> PERL Program

<210> 1

<211> 498

<212> PRT

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte ID No: 1632930CD1

<400> 1

Met	Ala	Glu	Asp	Ser	Glu	Ser	Ala	Ala	Ser	Gln	Gln	Ser	Leu	Glu
1				5					10					15
Leu	Asp	Asp	Gln	Asp	Thr	Cys	Gly	Ile	Asp	Gly	Asp	Asn	Glu	Glu
			20						25					30
Glu	Thr	Glu	His	Ala	Lys	Gly	Ser	Pro	Gly	Gly	Tyr	Leu	Gly	Ala
			35						40					45
Lys	Lys	Lys	Lys	Lys	Lys	Gln	Lys	Arg	Lys	Lys	Glu	Lys	Pro	Asn
			50						55					60
Ser	Gly	Gly	Thr	Lys	Ser	Asp	Ser	Ala	Ser	Asp	Ser	Gln	Glu	Ile
			65						70					75
Lys	Ile	Gln	Gln	Pro	Ser	Lys	Asn	Pro	Ser	Val	Pro	Met	Gln	Lys
			80						85					90
Leu	Gln	Asp	Ile	Gln	Arg	Ala	Met	Glu	Leu	Leu	Ser	Ala	Cys	Gln
			95						100					105
Gly	Pro	Ala	Arg	Asn	Ile	Asp	Glu	Ala	Ala	Lys	His	Arg	Tyr	Gln
			110						115					120
Phe	Trp	Asp	Thr	Gln	Pro	Val	Pro	Lys	Leu	Asp	Glu	Val	Ile	Thr
			125						130					135
Ser	His	Gly	Ala	Ile	Glu	Pro	Asp	Lys	Val	Asn	Val	Arg	Gln	Glu
			140						145					150

Pro Tyr Ser Leu	Pro Gln Gly Phe Met	Trp Asp Thr Leu Asp	Leu
155		160	165
Ser Asp Ala Glu	Val Leu Lys Glu Leu	Tyr Thr Leu Leu Asn	Glu
170		175	180
Asn Tyr Val Glu	Asp Asp Asp Asn Met	Phe Arg Phe Asp Tyr	Ser
185		190	195
Pro Glu Phe Leu	Leu Trp Ala Leu Arg	Pro Pro Gly Trp Leu	Leu
200		205	210
Gln Trp His Cys	Gly Val Arg Val Ser	Ser Asn Lys Lys Leu	Val
215		220	225
Gly Phe Ile Ser	Ala Ile Pro Ala Asn	Ile Arg Ile Tyr Asp	Ser
230		235	240
Val Lys Lys Met	Val Glu Ile Asn Phe	Leu Cys Val His Lys	Lys
245		250	255
Leu Arg Ser Lys	Arg Val Ala Pro Val	Leu Ile Arg Glu Ile	Thr
260		265	270
Arg Arg Val Asn	Leu Glu Gly Ile Phe	Gln Ala Val Tyr Thr	Ala
275		280	285
Gly Val Val Leu	Pro Lys Pro Ile Ala	Thr Cys Arg Tyr Trp	His
290		295	300
Arg Ser Leu Asn	Pro Arg Lys Leu Val	Glu Val Lys Phe Ser	His
305		310	315
Leu Ser Arg Asn	Met Thr Leu Gln Arg	Thr Met Lys Leu Tyr	Arg
320		325	330
Leu Pro Asp Val	Thr Lys Thr Ser Gly	Leu Arg Pro Met Glu	Pro
335		340	345
Lys Asp Ile Lys	Ser Val Arg Glu Leu	Ile Asn Thr Tyr Leu	Lys
350		355	360
Gln Phe His Leu	Ala Pro Val Met Asp	Glu Glu Glu Val Ala	His
365		370	375
Trp Phe Leu Pro	Arg Glu His Ile Ile	Asp Thr Phe Val Val	Glu
380		385	390
Ser Pro Asn Gly	Lys Leu Thr Asp Phe	Leu Ser Phe Tyr Thr	Leu
395		400	405
Pro Ser Thr Val	Met His His Pro Ala	His Lys Ser Leu Lys	Ala
410		415	420
Ala Tyr Ser Phe	Tyr Asn Ile His Thr	Glu Thr Pro Leu Leu	Asp
425		430	435
Leu Met Ser Asp	Ala Leu Ile Leu Ala	Lys Ser Lys Gly Phe	Asp
440		445	450
Val Phe Asn Ala	Leu Asp Leu Met Glu	Asn Lys Thr Phe Leu	Glu
455		460	465
Lys Leu Lys Phe	Gly Ile Gly Asp Gly	Asn Leu Gln Tyr Tyr	Leu
470		475	480
Tyr Asn Trp Arg	Cys Pro Gly Thr Asp	Ser Glu Lys Val Gly	Leu
485		490	495
Val Leu Gln			

<210> 2

<211> 360

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2682663CD1

<400> 2

```

Met Lys Ala Leu Ile Leu Val Gly Gly Tyr Gly Thr Arg Leu Arg
 1           5           10           15
Pro Leu Thr Leu Ser Thr Pro Lys Pro Leu Val Asp Phe Cys Asn
          20           25           30
Lys Pro Ile Leu Leu His Gln Val Glu Ala Leu Ala Ala Ala Gly
          35           40           45
Val Asp His Val Ile Leu Ala Val Ser Tyr Met Ser Gln Val Leu
          50           55           60
Glu Lys Glu Met Lys Ala Gln Glu Gln Arg Leu Gly Ile Arg Ile
          65           70           75
Ser Met Ser His Glu Glu Glu Pro Leu Gly Thr Ala Gly Pro Leu
          80           85           90
Ala Leu Ala Arg Asp Leu Leu Ser Glu Thr Ala Asp Pro Phe Phe
          95          100          105
Val Leu Asn Ser Asp Val Ile Cys Asp Phe Pro Phe Gln Ala Met
          110          115          120
Val Gln Phe His Arg His His Gly Gln Glu Gly Ser Ile Leu Val
          125          130          135
Thr Lys Val Glu Glu Pro Ser Lys Tyr Gly Val Val Val Cys Glu
          140          145          150
Ala Asp Thr Gly Arg Ile His Arg Phe Val Glu Lys Pro Gln Val
          155          160          165
Phe Val Ser Asn Lys Ile Asn Ala Gly Met Tyr Ile Leu Ser Pro
          170          175          180
Ala Val Leu Arg Arg Ile Gln Leu Gln Pro Thr Ser Ile Glu Lys
          185          190          195
Glu Val Phe Pro Ile Met Ala Lys Glu Gly Gln Leu Tyr Ala Met
          200          205          210
Glu Leu Gln Gly Phe Trp Met Asp Ile Gly Gln Pro Lys Asp Phe
          215          220          225
Leu Thr Gly Met Cys Leu Phe Leu Gln Ser Leu Arg Gln Lys Gln
          230          235          240
Pro Glu Arg Leu Cys Ser Gly Pro Gly Ile Val Gly Asn Val Leu
          245          250          255
Val Asp Pro Ser Ala Arg Ile Gly Gln Asn Cys Ser Ile Gly Pro
          260          265          270
Asn Val Ser Leu Gly Pro Gly Val Val Val Glu Asp Gly Val Cys
          275          280          285
Ile Arg Arg Cys Thr Val Leu Arg Asp Ala Arg Ile Arg Ser His
          290          295          300
Ser Trp Leu Glu Ser Cys Ile Val Gly Trp Arg Cys Arg Val Gly
          305          310          315
Gln Trp Val Arg Met Glu Asn Val Thr Val Leu Gly Glu Asp Val
          320          325          330

Ile Val Asn Asp Glu Leu Tyr Leu Asn Gly Ala Ser Val Leu Pro
          335          340          345
His Lys Ser Ile Gly Glu Ser Val Pro Glu Pro Arg Ile Ile Met
          350          355          360

```

<210> 3

<211> 519

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1265094CD1

<400> 3

Met	Ala	Glu	Glu	Arg	Val	Ala	Thr	Arg	Thr	Gln	Phe	Pro	Val	Ser	1	5	10	15
Thr	Glu	Ser	Gln	Lys	Pro	Arg	Gln	Lys	Lys	Ala	Pro	Glu	Phe	Pro	20	25	30	35
Ile	Leu	Glu	Lys	Gln	Asn	Trp	Leu	Ile	His	Leu	His	Tyr	Ile	Arg	40	45	50	55
Lys	Asp	Tyr	Glu	Ala	Cys	Lys	Ala	Val	Ile	Lys	Glu	Gln	Leu	Gln	60	65	70	75
Glu	Thr	Gln	Gly	Leu	Cys	Glu	Tyr	Ala	Ile	Tyr	Val	Gln	Ala	Leu	80	85	90	95
Ile	Phe	Arg	Leu	Glu	Gly	Asn	Ile	Gln	Glu	Ser	Leu	Glu	Leu	Phe	100	105	110	115
Gln	Thr	Cys	Ala	Val	Leu	Ser	Pro	Gln	Ser	Ala	Asp	Asn	Leu	Lys	120	125	130	135
Gln	Val	Ala	Arg	Ser	Leu	Phe	Leu	Leu	Gly	Lys	His	Lys	Ala	Ala	140	145	150	155
Ile	Glu	Val	Tyr	Asn	Glu	Ala	Ala	Lys	Leu	Asn	Gln	Lys	Asp	Trp	160	165	170	175
Glu	Ile	Ser	His	Asn	Leu	Gly	Val	Cys	Tyr	Ile	Tyr	Leu	Lys	Gln	180	185	190	195
Phe	Asn	Lys	Ala	Gln	Asp	Gln	Leu	His	Asn	Ala	Leu	Asn	Leu	Asn	200	205	210	215
Arg	His	Asp	Leu	Thr	Tyr	Ile	Met	Leu	Gly	Lys	Ile	His	Leu	Leu	220	225	230	235
Glu	Gly	Asp	Leu	Asp	Lys	Ala	Ile	Glu	Val	Tyr	Lys	Lys	Ala	Val	240	245	250	255
Glu	Phe	Ser	Pro	Glu	Asn	Thr	Glu	Leu	Leu	Thr	Thr	Leu	Gly	Leu	260	265	270	275
Leu	Tyr	Leu	Gln	Leu	Gly	Ile	Tyr	Gln	Lys	Ala	Phe	Glu	His	Leu	280	285	290	295
Gly	Asn	Ala	Leu	Thr	Tyr	Asp	Pro	Thr	Asn	Tyr	Lys	Ala	Ile	Leu	300	305	310	315
Ala	Ala	Gly	Ser	Met	Met	Gln	Thr	His	Gly	Asp	Phe	Asp	Val	Ala	320	325	330	335
Leu	Thr	Lys	Tyr	Arg	Val	Val	Ala	Cys	Ala	Val	Pro	Glu	Ser	Pro	340	345	350	355
Pro	Leu	Trp	Asn	Asn	Ile	Gly	Met	Cys	Phe	Phe	Gly	Lys	Lys	Lys	360	365	370	375
Tyr	Val	Ala	Ala	Ile	Ser	Cys	Leu	Lys	Arg	Ala	Asn	Tyr	Leu	Ala	380	385	390	

Ala	Leu	Ala	Gln	Tyr	Gln	Glu	Met	Glu	Lys	Lys	Val	Ser	Leu	Leu
									395					405
Lys	Asp	Asn	Ser	Ser	Leu	Glu	Phe	Asp	Ser	Glu	Met	Val	Glu	Met
									410					420
Ala	Gln	Lys	Leu	Gly	Ala	Ala	Leu	Gln	Val	Gly	Glu	Ala	Leu	Val
									425					435
Trp	Thr	Lys	Pro	Val	Lys	Asp	Pro	Lys	Ser	Lys	His	Gln	Thr	Thr
									440					450
Ser	Thr	Ser	Lys	Pro	Ala	Ser	Phe	Gln	Gln	Pro	Leu	Gly	Ser	Asn
									455					465
Gln	Ala	Leu	Gly	Gln	Ala	Met	Ser	Ser	Ala	Ala	Ala	Tyr	Arg	Thr
									470					480
Leu	Pro	Ser	Gly	Ala	Gly	Gly	Thr	Ser	Gln	Phe	Thr	Lys	Pro	Pro
									485					495
Ser	Leu	Pro	Leu	Glu	Pro	Glu	Pro	Ala	Val	Glu	Ser	Ser	Pro	Thr
									500					510
Glu	Thr	Ser	Glu	Gln	Ile	Arg	Glu	Lys						
									515					

<210> 4

<211> 225

<212> PRT

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte ID No: 1404963CD1

<400> 4

Met	Ala	Gly	Ser	Ser	Glu	Glu	Ala	Pro	Asp	Tyr	Gly	Arg	Gly	Val
1				5					10					15
Val	Ile	Met	Asp	Asp	Trp	Pro	Gly	Tyr	Asp	Leu	Asn	Leu	Phe	Thr
				20					25					30
Tyr	Pro	Gln	His	Tyr	Tyr	Gly	Asp	Leu	Glu	Tyr	Val	Leu	Ile	Pro
				35					40					45
His	Gly	Ile	Ile	Val	Asp	Arg	Ile	Glu	Arg	Leu	Ala	Lys	Asp	Ile
				50					55					60
Met	Lys	Asp	Ile	Gly	Tyr	Ser	Asp	Ile	Met	Val	Leu	Cys	Val	Leu
				65					70					75
Lys	Gly	Gly	Tyr	Lys	Phe	Cys	Ala	Asp	Leu	Val	Glu	His	Leu	Lys
				80					85					90
Asn	Ile	Ser	Arg	Asn	Ser	Asp	Arg	Phe	Val	Ser	Met	Lys	Val	Asp
				95					100					105
Phe	Ile	Arg	Leu	Lys	Ser	Tyr	Arg	Asn	Asp	Gln	Ser	Met	Gly	Glu
				110					115					120
Met	Gln	Ile	Ile	Gly	Gly	Gly	Asp	Leu	Ser	Thr	Leu	Ala	Gly	Lys
				125					130					135
Asn	Val	Leu	Ile	Val	Glu	Asp	Val	Val	Gly	Thr	Gly	Arg	Thr	Met
				140					145					150
Lys	Ala	Leu	Leu	Ser	Asn	Ile	Glu	Lys	Tyr	Arg	Pro	Asn	Met	Ile
				155					160					165
Lys	Val	Ala	Ser	Leu	Leu	Val	Lys	Arg	Thr	Ser	Arg	Ser	Asp	Gly
				170					175					180
Phe	Arg	Pro	Asp	Tyr	Ala	Gly	Phe	Glu	Ile	Pro	Asn	Leu	Phe	Val
				185					190					195
Val	Gly	Tyr	Ala	Leu	Asp	Tyr	Asn	Glu	Tyr	Phe	Arg	Asp	Leu	Asn

	200		205		210
His Ile Cys Val	Ile Asn Glu His Gly	Lys Glu Lys Tyr Arg	Val		
	215		220		225

<210> 5

<211> 338

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1405058CD1

<400> 5

Met Ala Ala Ser Gln Val Leu Gly Glu Lys Ile Asn Ile Leu Ser		
1	5	10
Gly Glu Thr Val Lys Ala Gly Asp Arg Asp Pro Leu Gly Asn Asp		
	20	25
Cys Pro Glu Gln Asp Arg Leu Pro Gln Arg Ser Trp Arg Gln Lys		
	35	40
Cys Ala Ser Tyr Val Leu Ala Leu Arg Pro Trp Ser Phe Ser Ala		
	50	55
Ser Leu Thr Pro Val Ala Leu Gly Ser Ala Leu Ala Tyr Arg Ser		
	65	70
His Gly Val Leu Asp Pro Arg Leu Leu Val Gly Cys Ala Val Ala		
	80	85
Val Leu Ala Val His Gly Ala Gly Asn Leu Val Asn Thr Tyr Tyr		
	95	100
Asp Phe Ser Lys Gly Ile Asp His Lys Lys Ser Asp Asp Arg Thr		
	110	115
Leu Val Asp Arg Ile Leu Glu Pro Gln Asp Val Val Arg Phe Gly		
	125	130
Val Phe Leu Tyr Thr Leu Gly Cys Val Cys Ala Ala Cys Leu Tyr		
	140	145
Tyr Leu Ser Pro Leu Lys Leu Glu His Leu Ala Leu Ile Tyr Phe		
	155	160
Gly Gly Leu Ser Gly Ser Phe Leu Tyr Thr Gly Gly Ile Gly Phe		
	170	175
Lys Tyr Val Ala Leu Gly Asp Leu Ile Ile Leu Ile Thr Phe Gly		
	185	190
Pro Leu Ala Val Met Phe Ala Tyr Ala Ile Gln Val Gly Ser Leu		
	200	205
Ala Ile Phe Pro Leu Val Tyr Ala Ile Pro Leu Ala Leu Ser Thr		
	215	220
Glu Ala Ile Leu His Ser Asn Asn Thr Arg Asp Met Glu Ser Asp		
	230	235
Arg Glu Ala Gly Ile Val Thr Leu Ala Ile Leu Ile Gly Pro Thr		
	245	250
Phe Ser Tyr Ile Leu Tyr Asn Thr Leu Leu Phe Leu Pro Tyr Leu		
	260	265
Val Phe Ser Ile Leu Ala Thr His Cys Thr Ile Ser Leu Ala Leu		
	275	280
Pro Leu Leu Thr Ile Pro Met Ala Phe Ser Leu Glu Arg Gln Phe		
	290	295
Arg Ser Gln Ala Phe Asn Lys Leu Pro Gln Arg Thr Ala Lys Leu		
	305	310
		315

Asn Leu Leu Leu Gly Leu Phe Tyr Val Phe Gly Ile Ile Leu Ala
 320 325 330
 Pro Ala Gly Ser Leu Pro Lys Ile
 335

<210> 6

<211> 619

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1420940CD1

<400> 6

Met Ser Gly Ile Lys Lys Gln Lys Thr Glu Asn Gln Gln Lys Ser
 1 5 10 15
 Thr Asn Val Val Tyr Gln Ala His His Val Ser Arg Asn Lys Arg
 20 25 30
 Gly Gln Val Val Gly Thr Arg Gly Gly Phe Arg Gly Cys Thr Val
 35 40 45
 Trp Leu Thr Gly Leu Ser Gly Ala Gly Lys Thr Thr Ile Ser Phe
 50 55 60
 Ala Leu Glu Glu Tyr Leu Val Ser His Ala Ile Pro Cys Tyr Ser
 65 70 75
 Leu Asp Gly Asp Asn Val Arg His Gly Leu Asn Arg Asn Leu Gly
 80 85 90
 Ser Ser Pro Gly Asp Arg Glu Glu Asn Ile Arg Arg Ile Ala Glu
 95 100 105
 Val Ala Lys Leu Phe Ala Asp Ala Gly Leu Val Cys Ile Thr Ser
 110 115 120
 Phe Ile Ser Pro Phe Ala Lys Asp Arg Glu Asn Ala Arg Lys Ile
 125 130 135
 His Glu Ser Ala Gly Leu Pro Phe Phe Glu Ile Phe Val Asp Ala
 140 145 150
 Pro Leu Asn Ile Cys Glu Ser Arg Asp Val Lys Gly Leu Tyr Lys
 155 160 165
 Arg Ala Arg Ala Gly Glu Ile Lys Gly Phe Thr Gly Ile Asp Ser
 170 175 180
 Asp Tyr Glu Lys Pro Glu Thr Pro Glu Arg Val Leu Lys Thr Asn
 185 190 195
 Leu Ser Thr Val Ser Asp Cys Val His Gln Val Val Glu Leu Leu
 200 205 210
 Gln Glu Gln Asn Ile Val Pro Tyr Thr Ile Ile Lys Asp Ile His
 215 220 225
 Glu Leu Phe Val Pro Glu Asn Lys Leu Asp His Val Arg Ala Glu
 230 235 240
 Ala Glu Thr Leu Pro Ser Leu Ser Ile Thr Lys Leu Asp Leu Gln
 245 250 255
 Trp Val Gln Val Leu Ser Glu Gly Trp Ala Thr Pro Leu Lys Gly
 260 265 270
 Phe Met Arg Glu Lys Glu Tyr Leu Gln Val Met His Phe Asp Thr
 275 280 285
 Leu Leu Asp Gly Met Ala Leu Pro Asp Gly Val Ile Asn Met Ser
 290 295 300
 Ile Pro Ile Val Leu Pro Val Ser Ala Glu Asp Lys Thr Arg Leu

	305		310		315
Glu Gly Cys Ser Lys Phe Val Leu Ala His Gly Gly Arg Arg Val					
	320		325		330
Ala Ile Leu Arg Asp Ala Glu Phe Tyr Glu His Arg Lys Glu Glu					
	335		340		345
Arg Cys Ser Arg Val Trp Gly Thr Thr Cys Thr Lys His Pro His					
	350		355		360
Ile Lys Met Val Met Glu Ser Gly Asp Trp Leu Val Gly Gly Asp					
	365		370		375
Leu Gln Val Leu Glu Lys Ile Arg Trp Asn Asp Gly Leu Asp Gln					
	380		385		390
Tyr Arg Leu Thr Pro Leu Glu Leu Lys Gln Lys Cys Lys Glu Met					
	395		400		405
Asn Ala Asp Ala Val Phe Ala Phe Gln Leu Arg Asn Pro Val His					
	410		415		420
Asn Gly His Ala Leu Leu Met Gln Asp Thr Arg Arg Arg Leu Leu					
	425		430		435
Glu Arg Gly Tyr Lys His Pro Val Leu Leu Leu His Pro Leu Gly					
	440		445		450
Gly Trp Thr Lys Asp Asp Asp Val Pro Leu Asp Trp Arg Met Lys					
	455		460		465
Gln His Ala Ala Val Leu Glu Glu Gly Val Leu Asp Pro Lys Ser					
	470		475		480
Thr Ile Val Ala Ile Phe Pro Ser Pro Met Leu Tyr Ala Gly Pro					
	485		490		495
Thr Glu Val Gln Trp His Cys Arg Ser Arg Met Ile Ala Gly Ala					
	500		505		510
Asn Phe Tyr Ile Val Gly Arg Asp Pro Ala Gly Met Pro His Pro					
	515		520		525
Glu Thr Lys Lys Asp Leu Tyr Glu Pro Thr His Gly Gly Lys Val					
	530		535		540
Leu Ser Met Ala Pro Gly Leu Thr Ser Val Glu Ile Ile Pro Phe					
	545		550		555
Arg Val Ala Ala Tyr Asn Lys Ala Lys Lys Ala Met Asp Phe Tyr					
	560		565		570
Asp Pro Ala Arg His Asn Glu Phe Asp Phe Ile Ser Gly Thr Arg					
	575		580		585
Met Arg Lys Leu Ala Arg Glu Gly Glu Asn Pro Pro Asp Gly Phe					
	590		595		600
Met Ala Pro Lys Ala Trp Lys Val Leu Thr Asp Tyr Tyr Arg Ser					
	605		610		615
Leu Glu Lys Asn					

<210> 7

<211> 284

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1784742CD1

<400> 7

Met Ala Glu Ser Glu Ala Glu Thr Pro Ser Thr Pro Gly Glu Phe

1

5

10

15

Glu Ser Lys Tyr Phe Glu Phe His Gly Val Arg Leu Pro Pro Phe
 20 25 30
 Cys Arg Gly Lys Met Glu Glu Ile Ala Asn Phe Pro Val Arg Pro
 35 40 45
 Ser Asp Val Trp Ile Val Thr Tyr Pro Lys Ser Gly Thr Ser Leu
 50 55 60
 Leu Gln Glu Val Val Tyr Leu Val Ser Gln Gly Ala Asp Pro Asp
 65 70 75
 Glu Ile Gly Leu Met Asn Ile Asp Glu Gln Leu Pro Val Leu Glu
 80 85 90
 Tyr Pro Gln Pro Gly Leu Asp Ile Ile Lys Glu Leu Thr Ser Pro
 95 100 105
 Arg Leu Ile Lys Ser His Leu Pro Tyr Arg Phe Leu Pro Ser Asp
 110 115 120
 Leu His Asn Gly Asp Ser Lys Val Ile Tyr Met Ala Arg Asn Pro
 125 130 135
 Lys Asp Leu Val Val Ser Tyr Tyr Gln Phe His Arg Ser Leu Arg
 140 145 150
 Thr Met Ser Tyr Arg Gly Thr Phe Gln Glu Phe Cys Arg Arg Phe
 155 160 165
 Met Asn Asp Lys Leu Gly Tyr Gly Ser Trp Phe Glu His Val Gln
 170 175 180
 Glu Phe Trp Glu His Arg Met Asp Ser Asn Val Leu Phe Leu Lys
 185 190 195
 Tyr Glu Asp Met His Arg Asp Leu Val Thr Met Val Glu Gln Leu
 200 205 210
 Ala Arg Phe Leu Gly Val Ser Cys Asp Lys Ala Gln Leu Glu Ala
 215 220 225
 Leu Thr Glu His Cys His Gln Leu Val Asp Gln Cys Cys Asn Ala
 230 235 240
 Glu Ala Leu Pro Val Gly Arg Gly Arg Val Gly Leu Trp Lys Asp
 245 250 255

Ile Phe Thr Val Ser Met Asn Glu Lys Phe Asp Leu Val Tyr Lys
 260 265 270
 Gln Lys Met Gly Lys Cys Asp Leu Thr Phe Asp Phe Tyr Leu
 275 280

<210> 8
 <211> 205
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1967138CD1

<400> 8
 Met Ala Asp Phe Cys Val Met Thr Arg Leu Leu Gly Tyr Val Asp
 1 5 10 15
 Pro Leu Asp Pro Ser Phe Val Ala Ala Val Ile Thr Ile Thr Phe
 20 25 30
 Asn Pro Leu Tyr Trp Asn Val Val Ala Arg Trp Glu His Lys Thr
 35 40 45
 Arg Lys Leu Ser Arg Ala Phe Gly Ser Pro Tyr Leu Ala Cys Tyr

	50		55		60									
Ser	Leu	Ser	Val	Thr	Ile	Leu	Leu	Leu	Asn	Phe	Leu	Arg	Ser	His
	65								70					75
Cys	Phe	Thr	Gln	Ala	Met	Leu	Ser	Gln	Pro	Arg	Met	Glu	Ser	Leu
	80								85					90
Asp	Thr	Pro	Ala	Ala	Tyr	Ser	Leu	Gly	Leu	Ala	Leu	Leu	Gly	Leu
	95								100					105
Gly	Val	Val	Leu	Val	Leu	Ser	Ser	Phe	Phe	Ala	Leu	Gly	Phe	Ala
	110								115					120
Gly	Thr	Phe	Leu	Gly	Asp	Tyr	Phe	Gly	Ile	Leu	Lys	Glu	Ala	Arg
	125								130					135
Val	Thr	Val	Phe	Pro	Phe	Asn	Ile	Leu	Asp	Asn	Pro	Met	Tyr	Trp
	140								145					150
Gly	Ser	Thr	Ala	Asn	Tyr	Leu	Gly	Trp	Ala	Ile	Met	His	Ala	Ser
	155								160					165
Pro	Thr	Gly	Leu	Leu	Leu	Thr	Val	Leu	Val	Ala	Leu	Thr	Tyr	Ile
	170								175					180
Val	Ala	Leu	Leu	Tyr	Glu	Glu	Pro	Phe	Thr	Ala	Glu	Ile	Tyr	Arg
	185								190					195
Gln	Lys	Ala	Ser	Gly	Ser	His	Lys	Arg	Ser					
	200								205					

<210> 9

<211> 414

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2124351CD1

<400> 9

Met	Thr	Lys	Ala	Arg	Leu	Phe	Arg	Leu	Trp	Leu	Val	Leu	Gly	Ser
1				5					10					15
Val	Phe	Met	Ile	Leu	Leu	Ile	Ile	Val	Tyr	Trp	Asp	Ser	Ala	Gly
				20					25					30
Ala	Ala	His	Phe	Tyr	Leu	His	Thr	Ser	Phe	Ser	Arg	Pro	His	Thr
				35					40					45
Gly	Pro	Pro	Leu	Pro	Thr	Pro	Gly	Pro	Asp	Arg	Asp	Arg	Glu	Leu
				50					55					60
Thr	Ala	Asp	Ser	Asp	Val	Asp	Glu	Phe	Leu	Asp	Lys	Phe	Leu	Ser
				65					70					75
Ala	Gly	Val	Lys	Gln	Ser	Asp	Leu	Pro	Arg	Lys	Glu	Thr	Glu	Gln
				80					85					90
Pro	Pro	Ala	Pro	Gly	Ser	Met	Glu	Glu	Ser	Val	Arg	Gly	Tyr	Asp
				95					100					105
Trp	Ser	Pro	Arg	Asp	Ala	Arg	Arg	Ser	Pro	Asp	Gln	Gly	Arg	Gln
				110					115					120
Gln	Ala	Glu	Arg	Arg	Ser	Val	Leu	Arg	Gly	Phe	Cys	Ala	Asn	Ser
				125					130					135
Ser	Leu	Ala	Phe	Pro	Thr	Lys	Glu	Arg	Ala	Phe	Asp	Asp	Ile	Pro
				140					145					150
Asn	Ser	Glu	Leu	Ser	His	Leu	Ile	Val	Asp	Asp	Arg	His	Gly	Ala
				155					160					165
Ile	Tyr	Cys	Tyr	Val	Pro	Lys	Val	Ala	Cys	Thr	Asn	Trp	Lys	Arg
				170					175					180

```

Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg Gly Ala Pro
      185                      190                      195
Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His Asn Ala
      200                      205                      210
Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly Lys
      215                      220                      225
Leu Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys
      230                      235                      240
Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe
      245                      250                      255
Arg Ser Lys Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe
      260                      265                      270
Ala Val Pro Met Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro
      275                      280                      285
Ala Ser Ala Arg Glu Ala Phe Arg Ala Gly Leu Lys Val Ser Phe
      290                      295                      300
Ala Asn Phe Ile Gln Tyr Leu Leu Asp Pro His Thr Glu Lys Leu
      305                      310                      315
Ala Pro Phe Asn Glu His Trp Arg Gln Val Tyr Arg Leu Cys His
      320                      325                      330
Pro Cys Gln Ile Asp Tyr Asp Phe Val Gly Lys Leu Glu Thr Leu
      335                      340                      345
Asp Glu Asp Ala Ala Gln Leu Leu Gln Leu Leu Gln Val Asp Arg
      350                      355                      360
Gln Leu Arg Phe Pro Pro Ser Tyr Arg Asn Arg Thr Ala Ser Ser
      365                      370                      375
Trp Glu Glu Asp Trp Phe Ala Lys Ile Pro Leu Ala Trp Arg Gln
      380                      385                      390

```

```

Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe Val Leu Phe Gly Tyr
      395                      400                      405
Pro Lys Pro Glu Asn Leu Leu Arg Asp
      410

```

```

<210> 10
<211> 660
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2153162CD1

```

```

<400> 10
Met Asp Asp Trp Lys Pro Ser Pro Leu Ile Lys Pro Phe Gly Ala
  1          5          10          15
Arg Lys Lys Arg Ser Trp Tyr Leu Thr Trp Lys Tyr Lys Leu Thr
      20          25          30
Asn Gln Arg Ala Leu Arg Arg Phe Cys Gln Thr Gly Ala Val Leu
      35          40          45
Phe Leu Leu Val Thr Val Ile Val Asn Ile Lys Leu Ile Leu Asp
      50          55          60
Thr Arg Arg Ala Ile Ser Glu Ala Asn Glu Asp Pro Glu Pro Glu
      65          70          75
Gln Asp Tyr Asp Glu Ala Leu Gly Arg Leu Glu Pro Pro Arg Arg

```

80	85	90
Arg Gly Ser Gly Pro Arg Arg Val Leu Asp Val Glu Val Tyr Ser		
95	100	105
Ser Arg Ser Lys Val Tyr Val Ala Val Asp Gly Thr Thr Val Leu		
110	115	120
Glu Asp Glu Ala Arg Glu Gln Gly Arg Gly Ile His Val Ile Val		
125	130	135
Leu Asn Gln Ala Thr Gly His Val Met Ala Lys Arg Val Phe Asp		
140	145	150
Thr Tyr Ser Pro His Glu Asp Glu Ala Met Val Leu Phe Leu Asn		
155	160	165
Met Val Ala Pro Gly Arg Val Leu Ile Cys Thr Val Lys Asp Glu		
170	175	180
Gly Ser Phe His Leu Lys Asp Thr Ala Lys Ala Leu Leu Arg Ser		
185	190	195
Leu Gly Ser Gln Ala Gly Pro Ala Leu Gly Trp Arg Asp Thr Trp		
200	205	210
Ala Phe Val Gly Arg Lys Gly Gly Pro Val Phe Gly Glu Lys His		
215	220	225
Ser Lys Ser Pro Ala Leu Ser Ser Trp Gly Asp Pro Val Leu Leu		
230	235	240
Lys Thr Asp Val Pro Leu Ser Ser Ala Glu Glu Ala Glu Cys His		
245	250	255
Trp Ala Asp Thr Glu Leu Asn Arg Arg Arg Arg Arg Phe Cys Ser		
260	265	270
Lys Val Glu Gly Tyr Gly Ser Val Cys Ser Cys Lys Asp Pro Thr		
275	280	285
Pro Ile Glu Phe Ser Pro Asp Pro Leu Pro Asp Asn Lys Val Leu		
290	295	300
Asn Val Pro Val Ala Val Ile Ala Gly Asn Arg Pro Asn Tyr Leu		
305	310	315
Tyr Arg Met Leu Arg Ser Leu Leu Ser Ala Gln Gly Val Ser Pro		
320	325	330
Gln Met Ile Thr Val Phe Ile Asp Gly Tyr Tyr Glu Glu Pro Met		
335	340	345
Asp Val Val Ala Leu Phe Gly Leu Arg Gly Ile Gln His Thr Pro		
350	355	360
Ile Ser Ile Lys Asn Ala Arg Val Ser Gln His Tyr Lys Ala Ser		
365	370	375
Leu Thr Ala Thr Phe Asn Leu Phe Pro Glu Ala Lys Phe Ala Val		
380	385	390
Val Leu Glu Glu Asp Leu Asp Ile Ala Val Asp Phe Phe Ser Phe		
395	400	405
Leu Ser Gln Ser Ile His Leu Leu Glu Glu Asp Asp Ser Leu Tyr		
410	415	420
Cys Ile Ser Ala Trp Asn Asp Gln Gly Tyr Glu His Thr Ala Glu		
425	430	435
Asp Pro Ala Leu Leu Tyr Arg Val Glu Thr Met Pro Gly Leu Gly		
440	445	450
Trp Val Leu Arg Arg Ser Leu Tyr Lys Glu Glu Leu Glu Pro Lys		
455	460	465
Trp Pro Thr Pro Glu Lys Leu Trp Asp Trp Asp Met Trp Met Arg		
470	475	480
Met Pro Glu Gln Arg Arg Gly Arg Glu Cys Ile Ile Pro Asp Val		
485	490	495
Ser Arg Ser Tyr His Phe Gly Ile Val Gly Leu Asn Met Asn Gly		

500	505	510
Tyr Phe His Glu Ala Tyr Phe Lys Lys His Lys Phe Asn Thr Val		
515	520	525
Pro Gly Val Gln Leu Arg Asn Val Asp Ser Leu Lys Lys Glu Ala		
530	535	540
Tyr Glu Val Glu Val His Arg Leu Leu Ser Glu Ala Glu Val Leu		
545	550	555
Asp His Ser Lys Asn Pro Cys Glu Asp Ser Phe Leu Pro Asp Thr		
560	565	570
Glu Gly His Thr Tyr Val Ala Phe Ile Arg Met Glu Lys Asp Asp		
575	580	585
Asp Phe Thr Thr Trp Thr Gln Leu Ala Lys Cys Leu His Ile Trp		
590	595	600
Asp Leu Asp Val Arg Gly Asn His Arg Gly Leu Trp Arg Leu Phe		
605	610	615
Arg Lys Lys Asn His Phe Leu Val Val Gly Val Pro Ala Ser Pro		
620	625	630
Tyr Ser Val Lys Lys Pro Pro Ser Val Thr Pro Ile Phe Leu Glu		
635	640	645
Pro Pro Pro Lys Glu Glu Gly Ala Pro Gly Ala Pro Glu Gln Thr		
650	655	660

<210> 11

<211> 386

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2617407CD1

<400> 11

Met Leu Leu Pro Lys Lys Met Lys Leu Leu Leu Phe Leu Val Ser		
1	5	10
Gln Met Ala Ile Leu Ala Leu Phe Phe His Met Tyr Ser His Asn		
20	25	30
Ile Ser Ser Leu Ser Met Lys Ala Gln Pro Glu Arg Met His Val		
35	40	45
Leu Val Leu Ser Ser Trp Arg Ser Gly Ser Ser Phe Val Gly Gln		
50	55	60
Leu Phe Gly Gln His Pro Asp Val Phe Tyr Leu Met Glu Pro Ala		
65	70	75
Trp His Val Trp Met Thr Phe Lys Gln Ser Thr Ala Trp Met Leu		
80	85	90
His Met Ala Val Arg Asp Leu Ile Arg Ala Val Phe Leu Cys Asp		
95	100	105
Met Ser Val Phe Asp Ala Tyr Met Glu Pro Gly Pro Arg Arg Gln		
110	115	120
Ser Ser Leu Phe Gln Trp Glu Asn Ser Arg Ala Leu Cys Ser Ala		
125	130	135
Pro Ala Cys Asp Ile Ile Pro Gln Asp Glu Ser Ser Pro Gly Leu		
140	145	150
Thr Ala Gly Ser Cys Ala Val Asn Ser Pro Leu Lys Leu Leu Glu		
155	160	165
Lys Ala Cys Arg Ser Tyr Ser His Val Val Leu Lys Glu Val Arg		
170	175	180

Phe	Phe	Asn	Leu	Gln	Ser	Leu	Tyr	Pro	Leu	Leu	Lys	Asp	Pro	Ser
				185					190					195
Leu	Asn	Leu	His	Ile	Val	His	Leu	Val	Arg	Asp	Pro	Arg	Ala	Val
				200					205					210
Phe	Arg	Ser	Arg	Glu	Arg	Thr	Lys	Gly	Asp	Leu	Met	Ile	Asp	Ser
				215					220					225
Arg	Ile	Val	Met	Gly	Gln	His	Glu	Gln	Lys	Leu	Lys	Lys	Glu	Asp
				230					235					240
Gln	Pro	Tyr	Tyr	Val	Met	Gln	Val	Ile	Cys	Gln	Ser	Gln	Leu	Glu
				245					250					255
Ile	Tyr	Lys	Thr	Ile	Gln	Ser	Leu	Pro	Lys	Ala	Leu	Gln	Glu	Arg
				260					265					270
Tyr	Leu	Leu	Val	Arg	Tyr	Glu	Asp	Leu	Ala	Arg	Ala	Pro	Val	Ala
				275					280					285
Gln	Thr	Ser	Arg	Met	Tyr	Glu	Phe	Val	Gly	Leu	Glu	Phe	Leu	Pro
				290					295					300
His	Leu	Gln	Thr	Trp	Val	His	Asn	Ile	Thr	Arg	Gly	Lys	Gly	Met
				305					310					315
Gly	Asp	His	Ala	Phe	His	Thr	Asn	Ala	Arg	Asp	Ala	Leu	Asn	Val
				320					325					330
Ser	Gln	Ala	Trp	Arg	Trp	Ser	Leu	Pro	Tyr	Glu	Lys	Val	Ser	Arg
				335					340					345
Leu	Gln	Lys	Ala	Cys	Gly	Asp	Ala	Met	Asn	Leu	Leu	Gly	Tyr	Arg
				350					355					360
His	Val	Arg	Ser	Glu	Gln	Glu	Gln	Arg	Asn	Leu	Leu	Leu	Asp	Leu
				365					370					375
Leu	Ser	Thr	Trp	Thr	Val	Pro	Glu	Gln	Ile	His				
				380					385					

<210> 12

<211> 803

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2963717CD1

<400> 12

Met	Ala	Glu	Ala	His	Gln	Ala	Val	Gly	Phe	Arg	Pro	Ser	Leu	Thr
1				5				10						15
Ser	Asp	Gly	Ala	Glu	Val	Glu	Leu	Ser	Ala	Pro	Val	Leu	Gln	Glu
				20				25						30
Ile	Tyr	Leu	Ser	Gly	Leu	Arg	Ser	Trp	Lys	Arg	His	Leu	Ser	Arg
				35				40						45
Phe	Trp	Asn	Asp	Phe	Leu	Thr	Gly	Val	Phe	Pro	Ala	Ser	Pro	Leu
				50				55						60
Ser	Trp	Leu	Phe	Leu	Phe	Ser	Ala	Ile	Gln	Leu	Ala	Trp	Phe	Leu
				65				70						75
Gln	Leu	Asp	Pro	Ser	Leu	Gly	Leu	Met	Glu	Lys	Ile	Lys	Glu	Leu
				80				85						90
Leu	Pro	Asp	Trp	Gly	Gly	Gln	His	His	Gly	Leu	Arg	Gly	Val	Leu
				95				100						105
Ala	Ala	Ala	Leu	Phe	Ala	Ser	Cys	Leu	Trp	Gly	Ala	Leu	Ile	Phe
				110				115						120
Thr	Leu	His	Val	Ala	Leu	Arg	Leu	Leu	Leu	Ser	Tyr	His	Gly	Trp

Leu Leu Glu Pro	125	His Gly Ala Met Ser Ser Pro Thr Lys Thr Trp	135
	140		150
Leu Ala Leu Val Arg	155	Ile Phe Ser Gly Arg His Pro Met Leu Phe	165
Ser Tyr Gln Arg Ser Leu Pro Arg Gln Pro Val Pro Ser Val Gln	170		180
Asp Thr Val Arg Lys Tyr Leu Glu Ser Val Arg Pro Ile Leu Ser	185		195
Asp Glu Asp Phe Asp Trp Thr Ala Val Leu Ala Gln Glu Phe Leu	200		210
Arg Leu Gln Ala Ser Leu Leu Gln Trp Tyr Leu Arg Leu Lys Ser	215		225
Trp Trp Ala Ser Asn Tyr Val Ser Asp Trp Trp Glu Glu Phe Val	230		240
Tyr Leu Arg Ser Arg Asn Pro Leu Met Val Asn Ser Asn Tyr Tyr	245		255
Met Met Asp Phe Leu Tyr Val Thr Pro Thr Pro Leu Gln Ala Ala	260		270
Arg Ala Gly Asn Ala Val His Ala Leu Leu Leu Tyr Arg His Arg	275		285
Leu Asn Arg Gln Glu Ile Pro Pro Thr Leu Leu Met Gly Met Arg	290		300
Pro Leu Cys Ser Ala Gln Tyr Glu Lys Ile Phe Asn Thr Thr Arg	305		315
Ile Pro Gly Val Gln Lys Asp Tyr Ile Arg His Leu His Asp Ser	320		330
Gln His Val Ala Val Phe His Arg Gly Arg Phe Phe Arg Met Gly	335		345
Thr His Ser Arg Asn Ser Leu Leu Ser Pro Arg Ala Leu Glu Gln	350		360
Gln Phe Gln Arg Ile Leu Asp Asp Pro Ser Pro Ala Cys Pro His	365		375
Glu Glu His Leu Ala Ala Leu Thr Ala Ala Pro Arg Gly Thr Trp	380		390
Ala Gln Val Arg Thr Ser Leu Lys Thr Gln Ala Ala Glu Ala Leu	395		405
Glu Ala Val Glu Gly Ala Ala Phe Phe Val Ser Leu Asp Ala Glu	410		420
Pro Ala Gly Leu Thr Arg Glu Asp Pro Ala Ala Ser Leu Asp Ala	425		435
Tyr Ala His Ala Leu Leu Ala Gly Arg Gly His Asp Arg Trp Phe	440		450
Asp Lys Ser Phe Thr Leu Ile Val Phe Ser Asn Gly Lys Leu Gly	455		465
Leu Ser Val Glu His Ser Trp Ala Asp Cys Pro Ile Ser Gly His	470		480
Met Trp Glu Phe Thr Leu Ala Thr Glu Cys Phe Gln Leu Gly Tyr	485		495
Ser Thr Asp Gly His Cys Lys Gly His Pro Asp Pro Thr Leu Pro	500		510
Gln Pro Gln Arg Leu Gln Trp Asp Leu Pro Asp Gln Ile His Ser	515		525
Ser Ile Ser Leu Ala Leu Arg Gly Ala Lys Ile Leu Ser Glu Asn	530		540
Val Asp Cys His Val Val Pro Phe Ser Leu Phe Gly Lys Ser Phe			

Ile Arg Arg Cys	545	550	555
His Leu Ser Ser Asp		Phe Ile Gln Ile	Ala
560	565		570
Leu Gln Leu Ala His	Phe Arg Asp Arg	Gly Gln Phe Cys Leu	Thr
575	580		585
Tyr Glu Ser Ala Met	Thr Arg Leu Phe	Leu Glu Gly Arg Thr	Glu
590	595		600
Thr Val Arg Ser Cys	Thr Arg Glu Ala	Cys Asn Phe Val Arg	Ala
605	610		615
Met Glu Asp Lys Glu	Lys Thr Asp Pro	Gln Cys Leu Ala Leu	Phe
620	625		630
Arg Val Ala Val Asp	Lys His Gln Ala	Leu Leu Lys Ala Ala	Met
635	640		645
Ser Gly Gln Gly Val	Asp Arg His Leu	Phe Ala Leu Tyr Ile	Val
650	655		660
Ser Arg Phe Leu His	Leu Gln Ser Pro	Phe Leu Thr Gln Val	His
665	670		675
Ser Glu Gln Trp Gln	Leu Ser Thr Ser	Gln Ile Pro Val Gln	Gln
680	685		690
Met His Leu Phe Asp	Val His Asn Tyr	Pro Asp Tyr Val Ser	Ser
695	700		705
Gly Gly Gly Phe Gly	Pro Ala Asp Asp	His Gly Tyr Gly Val	Ser
710	715		720
Tyr Ile Phe Met Gly	Asp Gly Met Ile	Thr Phe His Ile Ser	Ser
725	730		735
Lys Lys Ser Ser Thr	Lys Thr Asp Ser	His Arg Leu Gly Gln	His
740	745		750
Ile Glu Asp Ala Leu	Leu Asp Val Ala	Ser Leu Phe Gln Ala	Gly
755	760		765
Gln His Phe Lys Arg	Arg Phe Arg Gly	Ser Gly Lys Glu Asn	Ser
770	775		780
Arg His Arg Cys Gly	Phe Leu Ser Arg	Gln Thr Gly Ala Ser	Lys
785	790		795
Ala Ser Met Thr Ser	Thr Asp Phe		
800			

<210> 13

<211> 295

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3360857CD1

<400> 13

Met Val Asp Ser Val	Tyr Arg Thr Arg	Ser Leu Gly Val Ala	Ala
1	5	10	15
Glu Gly Leu Pro Asp	Gln Tyr Ala Asp	Gly Glu Ala Ala Arg	Val
20	25		30
Trp Gln Leu Tyr Ile	Gly Asp Thr Arg	Ser Arg Thr Ala Glu	Tyr
35	40		45
Lys Ala Trp Leu Leu	Gly Leu Leu Arg	Gln His Gly Cys Gln	Arg
50	55		60
Val Leu Asp Val Ala	Cys Gly Thr Gly	Val Asp Ser Ile Met	Leu
65	70		75

Val	Glu	Glu	Gly	Phe	Ser	Val	Thr	Ser	Val	Asp	Ala	Ser	Asp	Lys
				80					85					90
Met	Leu	Lys	Tyr	Ala	Leu	Lys	Glu	Arg	Trp	Asn	Arg	Arg	His	Glu
				95					100					105
Pro	Ala	Phe	Asp	Lys	Trp	Val	Ile	Glu	Glu	Ala	Asn	Trp	Met	Thr
				110					115					120
Leu	Asp	Lys	Asp	Val	Pro	Gln	Ser	Ala	Glu	Gly	Gly	Phe	Asp	Ala
				125					130					135
Val	Ile	Cys	Leu	Gly	Asn	Ser	Phe	Ala	His	Leu	Pro	Asp	Cys	Lys
				140					145					150
Gly	Asp	Gln	Ser	Glu	His	Arg	Leu	Ala	Leu	Lys	Asn	Ile	Ala	Ser
				155					160					165
Met	Val	Arg	Ala	Gly	Gly	Leu	Leu	Val	Ile	Asp	His	Arg	Asn	Tyr
				170					175					180
Asp	His	Ile	Leu	Ser	Thr	Gly	Cys	Ala	Pro	Pro	Gly	Lys	Asn	Ile
				185					190					195
Tyr	Tyr	Lys	Ser	Asp	Leu	Thr	Lys	Asp	Val	Thr	Thr	Ser	Val	Leu
				200					205					210
Ile	Val	Asn	Asn	Lys	Ala	His	Met	Val	Thr	Leu	Asp	Tyr	Thr	Val
				215					220					225
Gln	Val	Pro	Gly	Ala	Gly	Gln	Asp	Gly	Ser	Pro	Gly	Leu	Ser	Lys
				230					235					240
Phe	Arg	Leu	Ser	Tyr	Tyr	Pro	His	Cys	Leu	Ala	Ser	Phe	Thr	Glu
				245					250					255
Leu	Leu	Gln	Ala	Ala	Phe	Gly	Gly	Lys	Cys	Gln	His	Ser	Val	Leu
				260					265					270
Gly	Asp	Phe	Lys	Pro	Tyr	Lys	Pro	Gly	Gln	Thr	Tyr	Ile	Pro	Cys
				275					280					285
Tyr	Phe	Ile	His	Val	Leu	Lys	Arg	Thr	Asp					
				290					295					

<210> 14

<211> 575

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3449671CD1

<400> 14

Met	Thr	Ser	Lys	Lys	Leu	Val	Asn	Ser	Val	Ala	Gly	Cys	Ala	Asp
1				5					10					15
Asp	Ala	Leu	Ala	Gly	Leu	Val	Ala	Cys	Asn	Pro	Asn	Leu	Gln	Leu
				20					25					30
Leu	Gln	Gly	His	Arg	Val	Ala	Leu	Arg	Ser	Asp	Leu	Asp	Ser	Leu
				35					40					45
Lys	Gly	Arg	Val	Ala	Leu	Leu	Ser	Gly	Gly	Gly	Ser	Gly	His	Glu
				50					55					60
Pro	Ala	His	Ala	Gly	Phe	Ile	Gly	Lys	Gly	Met	Leu	Thr	Gly	Val
				65					70					75
Ile	Ala	Gly	Ala	Val	Phe	Thr	Ser	Pro	Ala	Val	Gly	Ser	Ile	Leu
				80					85					90
Ala	Ala	Ile	Arg	Ala	Val	Ala	Gln	Ala	Gly	Thr	Val	Gly	Thr	Leu
				95					100					105
Leu	Ile	Val	Lys	Asn	Tyr	Thr	Gly	Asp	Arg	Leu	Asn	Phe	Gly	Leu

110	115	120
Ala Arg Glu Gln	Ala Arg Ala Glu Gly	Ile Pro Val Glu Met Val
125	130	135
Val Ile Gly Asp	Asp Ser Ala Phe Thr	Val Leu Lys Lys Ala Gly
140	145	150
Arg Arg Gly Leu	Cys Gly Thr Val Leu	Ile His Lys Val Ala Gly
155	160	165
Ala Leu Ala Glu	Ala Gly Val Gly Leu	Glu Ile Ala Lys Gln
170	175	180
Val Asn Val Val	Thr Lys Ala Met Gly	Thr Leu Gly Val Ser Leu
185	190	195
Ser Ser Cys Ser	Val Pro Gly Ser Lys	Pro Thr Phe Glu Leu Ser
200	205	210
Ala Asp Glu Val	Glu Leu Gly Leu Gly	Ile His Gly Glu Ala Gly
215	220	225
Val Arg Arg Ile	Lys Met Ala Thr Ala	Asp Glu Ile Val Lys Leu
230	235	240
Met Leu Asp His	Met Thr Asn Thr Thr	Asn Ala Ser His Val Pro
245	250	255
Val Gln Pro Gly	Ser Ser Val Val Met	Met Val Asn Asn Leu Gly
260	265	270
Gly Leu Ser Phe	Leu Glu Leu Gly Ile	Ile Ala Asp Ala Thr Val
275	280	285
Arg Ser Leu Glu	Gly Arg Gly Val Lys	Ile Ala Arg Ala Leu Val
290	295	300
Gly Thr Phe Met	Ser Ala Leu Glu Met	Pro Gly Ile Ser Leu Thr
305	310	315
Leu Leu Leu Val	Asp Glu Pro Leu Leu	Lys Leu Ile Asp Ala Glu
320	325	330
Thr Thr Ala Ala	Ala Trp Pro Asn Val	Ala Ala Val Ser Ile Thr
335	340	345
Gly Arg Lys Arg	Ser Arg Val Ala Pro	Ala Glu Pro Gln Glu Ala
350	355	360
Pro Asp Ser Thr	Ala Ala Gly Gly Ser	Ala Ser Lys Arg Met Ala
365	370	375
Leu Val Leu Glu	Arg Val Cys Ser Thr	Leu Leu Gly Leu Glu Glu
380	385	390
His Leu Asn Ala	Leu Asp Arg Ala Ala	Gly Asp Gly Asp Cys Gly
395	400	405
Thr Thr His Ser	Arg Ala Ala Arg Ala	Ile Gln Glu Trp Leu Lys
410	415	420
Glu Gly Pro Pro	Pro Ala Ser Pro Ala	Gln Leu Leu Ser Lys Leu
425	430	435
Ser Val Leu Leu	Leu Glu Lys Met Gly	Gly Ser Ser Gly Ala Leu
440	445	450
Tyr Gly Leu Phe	Leu Thr Ala Ala Ala	Gln Pro Leu Lys Ala Lys
455	460	465
Thr Ser Leu Pro	Ala Trp Ser Ala Ala	Met Asp Ala Gly Leu Glu
470	475	480
Ala Met Gln Lys	Tyr Gly Lys Ala Ala	Pro Gly Asp Arg Thr Met
485	490	495
Leu Asp Ser Leu	Trp Ala Ala Gly Gln	Glu Leu Gln Ala Trp Lys
500	505	510
Ser Pro Gly Ala	Asp Leu Leu Gln Val	Leu Thr Lys Ala Val Lys
515	520	525
Ser Ala Glu Ala	Ala Ala Glu Ala Thr	Lys Asn Met Glu Ala Gly

530	535	540
Ala Gly Arg Ala Ser Tyr Ile Ser Ser	Ala Arg Leu Glu Gln Pro	
545	550	555
Asp Pro Gly Ala Val Ala Ala Ala Ala	Ile Leu Arg Ala Ile Leu	
560	565	570
Glu Val Leu Gln Ser		
575		

<210> 15
 <211> 180
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5497787CD1

<400> 15	
Met Ala Ser Ser Val Gly Asn Val Ala Asp Ser Thr Glu Pro Thr	
1 5 10 15	
Lys Arg Met Leu Ser Phe Gln Gly Leu Ala Glu Leu Ala His Arg	
20 25 30	
Glu Tyr Gln Ala Gly Asp Phe Glu Ala Ala Glu Arg His Cys Met	
35 40 45	
Gln Leu Trp Arg Gln Glu Pro Asp Asn Thr Gly Val Leu Leu Leu	
50 55 60	
Leu Ser Ser Ile His Phe Gln Cys Arg Arg Leu Asp Arg Ser Ala	
65 70 75	
His Phe Ser Thr Leu Ala Ile Lys Gln Asn Pro Leu Leu Ala Glu	
80 85 90	
Ala Tyr Ser Asn Leu Gly Asn Val Tyr Lys Glu Arg Gly Gln Leu	
95 100 105	
Gln Glu Ala Ile Glu His Tyr Arg His Ala Leu Arg Leu Lys Pro	
110 115 120	
Asp Phe Ile Asp Gly Tyr Ile Asn Leu Ala Ala Ala Leu Val Ala	
125 130 135	
Ala Gly Asp Met Glu Gly Ala Val Gln Ala Tyr Val Ser Ala Leu	
140 145 150	
Gln Tyr Asn Pro Asp Leu Tyr Cys Val Arg Ser Asp Leu Gly Asn	
155 160 165	
Leu Leu Lys Ala Leu Gly Arg Leu Glu Glu Ala Lys Val Gly Val	
170 175 180	

<210> 16
 <211> 2120
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1632930CB1

<400> 16
 gatggcgagg gacagcgagt ctgcggccag ccagcagagc ctggaactgg acgaccagga 60
 cacgtgcggg atagacgggg acaatgagga ggagacggag cacgccaaag gaagtcttgg 120

```

agggtatttg ggagccaaaa agaaaaagaa gaaacagaag agaaaaaagg agaaacccaaa 180
ttccggaggc accaagtcag actcggcattc tgattcccag gagattaaaa ttcagcagcc 240
ttcgaaaaat cccagtgttc caatgcagaa gttgcaggat atccagagag caatggagct 300
gctatccgca tgccagggcc cagccaggaa cattgatgag gctgcaaagc acagatacca 360
gttttgggac acacaaccgg taccaaaact agatgaagtc ataacatctc atggtgcaat 420
tgaaccagat aaagtcaacg tacggcaaga accgtattct ttgccacagg gttttatgtg 480
ggacacttta gacttgagtg atgccgaagt gctcaaggag ttatacacgt tgttaaata 540
gaattacgta gaagatgatg acaatatgtt ccgatttgac tattcacccg agttcctgtt 600
gtgggctctg cgtccaccag gctggctcct gcagtggcac tgtggggcca gagtgtcttc 660
aaataaaaaa ctggtcgggt tcataagtgc catcccagca aacattcgga tttatgacag 720
tgtgaagaag atggtagaaa tcaactttct ttgtgttcat aagaagttga gatcgaaacg 780
ggtagcccca gtgctaatac gagagatcac tagaagagtg aacctggaag ggatcttcca 840
ggctgtgtac accgcgggag tggttcttcc taagcccata gccacatgca gatactggca 900
tcgatcacta aacccagaa aattggtaga agtgaaattt tctcacttga gtgaaatat 960
gactttacag agaacaatga agctatacag acttccagat gttacaaaga cttcagggtt 1020
gagaccaatg gaacccaaaag atatcaaata agttcgagaa ttaatcaaca cttacctgaa 1080
gcagtttcat ctggctccag tgatggatga agaggaagta gccactgggt tcctcccccg 1140
ggagcacatt attgacacgt ttgtagtggg gagccccaac ggtaaaactga ctgatttctt 1200
gagcttctat acgctcccc ctacgggtgat gcaccaccct gctcacaaaga gcctcaaagc 1260
cgctactcca ttctacaaca tccacacaga gacgcccctg ctggacctca tgagcgacgc 1320
gctcatctg gctaaatcga aaggatttga tgtattcaat gcactggatt tgatggaaaa 1380
taagacattc ttggaaaaac tcaagtttgg tataggagat ggcaatttgc agtattacct 1440
gtacaattgg aggtgtccag gtacagattc tgaaaagggt ggactagtac tacaatagat 1500
ggatattttt atttctagaa ctctgacatc atcatttgtt aatatttaat gatttctgga 1560
actgccattc caaagaagaa taaaagcaca actcaagtga aattgaagta gtcgataatc 1620
agaaaagatg acaaaagtcc acatgtgaca tttgtacgtt tctagctaga atgttaaact 1680
tcattctttt ttactgttg acctatttgt gggagggatg aaaggctaca aagagcacat 1740
tcttgtaatt ttcaaatttt tgctgtctc ttgaagaggt attttttcac ccttagaaaa 1800
gggactgttt ttctatggac taagtagaag ttacagagtc atgtaagaaa atctttgcta 1860
ttgtgtggag agaaattgct gcatttctgt ttcttaagtg atggtacatt tgtccatgta 1920
acagaacaaa agatccattt ggaaattttt tttactggta tcacctaca tggatcact 1980
gggaacattt atggaatcaa cacttctgta gctcagtgac aggtggtggt tgtttaagt 2040
cagagcaata ttaaaatgta ctggtgacta gtacatgtat ttctccataa gcagagttgc 2100
cgaatcaata aacatgcaat 2120

```

<210> 17

<211> 1559

<212> DNA

<213> Homo sapiens

<<220>

<221> misc_feature

<223> Incyte ID No: 2682663CB1

<400> 17

```

gcagccgtct acccggtgtc gcgttctgtg ttgtggcgcc cctggatccg gcgtcagggc 60
gaccggggcg acgaggtgga gccagagctc gtcaggcggg ttggtgaagg gcgcggggcc 120
gggcacggcg ttgggagtgc gcggcaggga ccggccaggc gggctgcagg cacctcagag 180
cccgggacac cccctcaacg tccgcaggcg cgatgaaggc actgatctta gtggggggct 240
atgggacggc gctacggccg ctgacgctga gcaccccgaa gccactgggt gacttctgca 300
ataagcccat cttgctgcac caagtggagg cgctagccgc ggcaggcgtg gaccacgtga 360
tcctggccgt gagctacatg tcgcagggtc tggagaagga aatgaaggca caggagcaga 420
ggctgggaat ccgaatctcc atgtcccatg aagaggagcc tttggggaca gctggggccc 480
tggcgctggc ccgtgacctt ctctctgaga ctgcagacc tttcttcgtc ctcaacagt 540
acgtgatctg cgatttcccc ttccaagcca tgggtgcagt ccaccggcac catggccagg 600
agggtcccat cctggtgacc aagggtggag aaccctccaa gtacggtgtg gtggtgtgtg 660

```

```

aggctgacac aggccgcatt caccggttcg tggagaagcc acagggtgtt gtgtccaata 720
agatcaacgc aggcattgtac atcctgagcc ctgcagtgtc gcggcgcatc cagctgcagc 780
ctacgtccat tgagaaggag gtcttcccca ttatggccaa ggaggggcag ctatatgcca 840
tggagttaca gggcttcttg atggacattg ggcagcccaa ggacttcctc actggcatgt 900
gcctcttctc gcagtctactg aggcagaagc agcctgagcg gctgtgctca ggccctggca 960
ttgtgggcaa cgtgctggtg gacccaagtg cccgcacg cgagaactgc agcattggcc 1020
ccaatgtgag cctgggacct ggcgtggtg tcgaagatgg tgtgtgtatc cggcggtgca 1080
cgggtgctgc ggatgcccgg atccgttccc attcctggct tgagtccctg attgtgggct 1140
ggcgtgcccg cgtgggtcag tgggtacgca tggagaacgt gacagtgtct ggtgaggacg 1200
tcatagttaa tgatgagctc tacctcaacg gagccagcgt gctgccccac aagtctattg 1260
gcgagtcatg gccagagcct cgtatcatca tgtgagggga tgcagtgggg ctggccgagc 1320
cccggtttc ccatcagcaa ggggagtgtt ggctgacac atcagaagac cctggacttg 1380
tcattatttg tctgggggga actgggtgaa gctgaagctg ttggacacct gccttctcat 1440
gtggacatca tctggcagga tccctgctgg gcacacccca caaacccac tccctcaaga 1500
agggccaggg ccagggtgtg atggaataat aatttaatgc tcaactgtgaa aaaaaaaaa 1559

```

<210> 18

<211> 2465

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1265094CB1

<400> 18

```

gctgagctaa aatggctgag gagagagtcg cgacgagaac tcaatttcct gtatctactg 60
agtctcaaaa accccggcag aaaaaagctc cagagtttcc tattttggag aagcagaact 120
ggttgattca tcttcattat atccggaaag attatgaagc ctgcaaggct gttatcaaag 180
aacagcttca agagactcag ggattgtgtg aatatgctat ctatgtccaa gcattgatat 240
ttgccttaga aggaaatc caagaatccc tagaactctt ccagacatgt gcagttctta 300
gtcctcagag tgctgataac ctcaagcagg tggccagatc tttatttctt ttgggaaaac 360
ataaagctgc cattgaagta tataatgaag cagctaaact caaccagaaa gattgggaga 420
tcagccataa cctaggagtt tgctacatat acctgaagca gttcaacaag gcacaagacc 480
agttgcacaa tgccctgaat cttaataggc acgatctgac ttatataatg ctggggaaga 540
tccacttgct ggaggagac ttggacaagg ccattgaagt ctacaagaaa gcagtggagt 600
tctcaccaga aaatacagag ctctttacaa ctcttaggatt actctactta cagctcggca 660
tttaccagaa ggcatttgaa catcttgga atgcactgac ttatgacctt accaactaca 720
aggccatctt ggcagcaggc agcatgatgc agaccacagg ggactttgat gttgccctca 780
ccaaatacag agttgtggct tgtgctgttc cagaaagtcc tccactctgg aataacattg 840
gaatgtgttt ctttggcaag aagaaatatg tggcggccat cagctgcctg aaacgagcca 900
actacttggc acccttcgat tggaagattc tgtataattt gggccttgtc catttgacca 960
tgcagcagta tgcacagct tttcattttc tcagtgcggc catcaacttc cagccaaaga 1020
tgggggagct ctacatgctc ttggcagtgg ctctgaccaa tctggaagat acagaaaatg 1080
ccaagagagc ctacgcagaa gcagtccacc tggataagtg taacccttta gtaaacctga 1140
actatgctgt gctgctgtac aaccagggcg agaagaagaa cgccctggcc caatatcagg 1200
agatggagaa gaaagtcagc ctactcaagg acaatagctc tctggaattt gactctgaga 1260
tggtggagat ggctcagaag ttgggagctg ctctccaggt tggggaggca ctggtctgga 1320
ccaaaccagt taaagatccc aaatcaaagc accagaccac ttcaaccagc aaacctgcca 1380
gtttccagca gcctctgggc tctaatacag ctctaggaca ggcaatgtct tcagcagctg 1440
catacaggac gctcccctca ggtgctggag gaacatccca gttcacaaag ccccatctc 1500
ttcctctgga gccagagcct gcggtggaat caagtccaac tgaaacatca gaacaaataa 1560
gagagaaata agaatagaat gaatgacccc aaaatagggt tttcttgggc gaggatgtgc 1620
tggattagga aaggtgacat gacacaggca gagcagagtg gcacccacca cagaatacag 1680
tgtgtgttat tacgaggagc cagcagttga gcctaaggte cttctaccta cctggtattg 1740
gcatttgagg tcggaaaacc tctactgccc cataagccag gaaaagtga aagagaacac 1800

```

```

agttccttta agaactggca gcaaggcttg aggccttatg tatgtagctg agtcagcaag 1860
gtacatgatg ctgtctgctt tcaaaaggac ttttctctcc tagctgactg actccttcc 1920
tagttcaagg aacagctgag acagacctct gctgagtagc tctgtgatga caaagccttg 1980
gtttaactga ggtgatcctc aggttgtagg gtttattagt cccaaggca aacacaaata 2040
ttagattaat aatccaactt taatagtata catttaaaag aaaaaaaca aaagcccttg 2100
aagttgaggc caagcctgct gagtattgca gctgcatttg cccaaaggga atccagaaca 2160
agtcacctcc tgtattttgt tcttgagagg ggtcagctca gaagctagat cctatcagga 2220
tgaggagcag cagcccaggg cttgtctgga tcagcaccaa cgatttttaa gaaaaaggga 2280
agagtttctt agatgagtaa ttgttattga agatagtcag tgataaccac tgaccagatg 2340
ctatcaatac actatgtgtc ctttttagaa taaagattac atatcatcat tcctttgggg 2400
aaaattgtta ttcaggtata aaaaacaagag atcataataa aaacctaaaa gaacctaaaa 2460
aaaaa 2465

```

<210> 19

<211> 1927

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1404963CB1

<400> 19

```

gcgttccccg ggagaaacat ggccgggagc agcgaggagg cgccagacta cgggagaggc 60
gtcgtgatta tggatgattg gccagggtat gacttgaatt tattcacgta cccacagcac 120
tattatggag acttgagta tgcctcatc cctcatggta tcattgtgga cagaattgag 180
cggtggcca aggatattat gaaagacata ggatatagtg acatcatggt cctgtgtgtg 240
cttaaaggag gttacaaatt ctgtgctgat ctcgtagaac accttaagaa catcagccga 300
aattcagatc gatttgcctc aatgaagggt gatttcatca gactaaaaag ttacaggaa 360
gaccagtcca tgggtgagat gcagataatc ggaggcgggtg atctttcaac gctggctgga 420
aagaatgttc tcattgttga ggatgtgtc ggaactggga ggaccatgaa agcactactc 480
agcaatatag agaaatacag gcccaacatg attaaggtag ccagtttgtt ggtgaagaga 540
acatccagaa gtgacgctt tagacctgac tatgctggat ttgagattcc aaacttattt 600
gtggtgggat atgccttaga ttacaatgaa tacttcagag atctgaatca catatgcgtc 660
atcaatgagc acggtaaaga aaaatatcga gtctaaagac atgaattctc accactaaag 720
tcccagatag catcatattt acgcctgtac ttgggaagcc agctgtcaag tttgtcccc 780
caggcatctt cactcagcag gatataaaag aaaaaaatgt tcaaatagaa gagctttctt 840
ttctgagggt aatataaaga gtatcaaagg ttctaagga aaagaaagca gtgcttttat 900
ttgacttgtt ccaaattaaa cactccgcct tgtgactcag caatgctatc taccttcaca 960
ctcctgagct cgccttcct ttgttttgat acagtcatta tatttgatta gtattcccag 1020
gaatacccc acctagttag tcaaatattt ttcacttaac tttttatact cttatttttg 1080
taataagctt acaatattaa gaagctgggg actttttttt aactgaagac ttgagcccc 1140
tataccggga atgcagctat taatagattc ccatatttta aaaggaggga aaggacaatt 1200
taataaaat ttctgtttgt gcatttctga caggccatta ttatctgctt tgacaaagcc 1260
ttctgaaac gcagtgtaca atgaatctta atgatgttat gaaacgagct ttgctcgggg 1320
ctcttgattg gagcttcagg tatgtgatga cggatgttca tgtatgcatg gatgtactca 1380
actgtgttta atactctgaa ttttaattag aaaaaaatac aatagcagca aggccttggt 1440
ttctaagctg tatcctttta ttcatgtggg acatgagcaa atggcagaat taggggcgag 1500
tgctttcaat gtcgaaact aagcaagtat aaatttttcc tcttatttgc atgaaaggac 1560
aagacactgt tatgccctgt cctaaatgtg aagacagagg ttgaattttt taaaaaatat 1620
ctttaaaga ctgatcaca aatccaaggt gctacaggaa acaagcacac tcaagaaagt 1680
ttttttctga ataacatttt tttccaattt ctccgtttta taagacattt cctaatttat 1740
ggggatttta attgaaaata aacttgagtc ccaatagagc tgtttttttc tcacttccta 1800
caaatgcaa atgcaaaata aataactaag cagcttttgt ttggttctga accgtatgtg 1860
gcgtattgtt attaggttct agcttccttt aaactaataa agaataagaa aacttaaaaa 1920
aaaaaaa 1927

```

<210> 20
 <211> 1715
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 1405058CB1

<400> 20
 ggctcagccg tgggctctaa cgcggggctg ggggccggag acagacttcg cccaggtgac 60
 gggtagtagg ggccggcgccg cttggcctcg tggggtgtaa gaccacttg ctggtgcccc 120
 cggaccttgc cgccacacca gccctgtcct gggcggaac cgaaggaagg tggggccctg 180
 ctgccccgcc ccgtccttcc tcttcccg ggcgtcactg tgcgtggctc acttttagag 240
 ttactttcaa ccacgtggag cttccatggc ggcctctcag gtcctggggg agaagattaa 300
 catcttgtcg ggagagactg tcaaagctgg ggacagggac ccgctgggga acgactgtcc 360
 cgagcaagat aggtcccccc agcgtcctcg gaggcagaag tgtgcctcct acgtgttggc 420
 cctgaggccc tggagcttca gtgcctcact cacaccgggt gccctgggca gtgcccttgc 480
 ctacagatcc caccgtgtcc tggatcccag gctcttgggt ggttgtgccc tggctgtcct 540
 ggctgtgcac ggggccggtg atttgggtcaa cacttactat gacttttcca agggcattga 600
 ccacaaaaag agtgatgaca ggacacttgt ggaccgaatc ttggagccgc aggatgtcgt 660
 ccggttcgga gtcttctct acacgttggg ctgcgtctgt gccgcttgc tctactacct 720
 gtccccctcg aaactggagc acttggctct tatctacttt ggaggcctgt ctggctcctt 780
 tctctacaca ggaggaattg gattcaagta cgtggctctg ggagacctca tcatcctcat 840
 cacttttggc ccgctggctg tgatgttcgc ctacgccatc cagggtggggc ccctggccat 900
 cttccactg gtctatgcc accccctgc cctcagcacc gaggccattc tccattccaa 960
 caacaccagg gacatggagt ccgaccggga ggctgggtatc gtcacgtggt ccctcctcat 1020
 cggccccacg ttctctaca ttctctacaa cacactgtct tcctgacct acctggtctt 1080
 cagcatcctg gccacacact gcaccatcag cctggcactc cccctgctta ccattcccat 1140
 ggcttcttcc cttgagagac agtttcgaag ccaggccttc aacaaactgc cccagaggac 1200
 tgccaagctc aacctcctgc tgggactttt ctatgtcttt ggcatcattc tggcaccagc 1260
 aggcagtctg cccaaaattt aaggggacaa gtagctcccc ccacgacatg tctccccctt 1320
 ttagaatata ttaaagtcag agtctctgag gaaggaatgt gatttggcag tcagggtact 1380
 aagcatgggt gggaactcct gccttataaa aattgttttt gtgttcttaa agataatatg 1440
 ttgtttttct gttttttgtt ttttccattt tatggggaat ttaaaaacca ttcttgcata 1500
 agaagggtgaa ttaggcgcag ggtctttgtt ttattaataa tttccactag aggggtgttc 1560
 caggtcactt ttcagtgaag tggacttagt tctccttgt tctgtacaaa atgtctccag 1620
 actttgtaaa ggagctgcc agtttggcct cctgtcccga aaagacccta ataactaggc 1680
 agagtgttgt cctgctttct tcgtctcgta ggata 1715

<210> 21
 <211> 2617
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1420940CB1

<400> 21
 tgctgctgct gctgctgcgc ccgcgcgcgc cgccgtccct ggcgtccttcg gtctctgctc 60
 ccgggaccgc ggctccgcgc cagccagcca gcatgtcggg gatcaagaag caaaagacgc 120
 agaaccagca gaaatccacc aatgtagtct atcaggccca ccatgtgagc aggaataaga 180
 gagggcaagt ggttgggaaca aggggtgggt tccgaggatg taccgtgtgg ctaacaggtc 240
 tctctggtgc tggaaaaaca acgataagtt ttgccctgga ggagtacctt gtctcccatg 300

```

ccatcccttg ttactccctg gatggggaca atgtccgtca tggccttaac agaaatctcg 360
gatcctctcc tggggacaga gaggaaaata tccgccggat tgctgaggtg gctaagctgt 420
ttgtgatgc tgggtctggtc tgcattacca gctttatttc tccattcgca aaggatcgtg 480
agaatgcccc caaaatacat gaatcagcag ggctgccatt ctttgaaata tttgtagatg 540
cacctctaaa tatttgtgaa agcagagacg taaaaggcct ctataaaagg gccagagctg 600
gggagattaa aggatttaca ggtattgatt ctgattatga gaaacctgaa actcctgagc 660
gtgtgcttaa aaccaatttg tccacagtga gtgactgtgt ccaccaggta gtggaacttc 720
tgcaagagca gaacattgta ccctatacta taatcaaaga tatccacgaa ctctttgtgc 780
cggaaaacaa acttgaccac gtccgagctg aggctgaaac tctcccttca ttatcaatta 840
ctaagctgga tctccagtgg gtccaggttt tgagcgaagg ctggggccact cccctcaaag 900
gtttcatgcy ggagaaagag tacttacagg ttatgcactt tgacaccctg ctagatggca 960
tggcccttcc tgatggcgtg atcaacatga gcatcccat tgtactgcc gtctctgcag 1020
aggataagac acggctggaa ggggtgcagca agtttgcct ggcacatggt ggacggaggg 1080
tagctatctt acgagacgct gaattctatg aacacagaaa agaggaacgc tgttcccgtg 1140
tttgggggac aacatgtaca aaacaccccc atatcaaaat ggtgatggaa agtggggact 1200
ggctgggttg tggagacctt cagggtgctg agaaaataag atggaatgat gggctggacc 1260
aataccgtct gacacctctg gagctcaaac agaaatgtaa agaaatgaat gctgatgcgg 1320
tgtttgcatt ccagttgcgc aatcctgtcc acaatggcca tgccctgttg atgcaggaca 1380
ctgcgcgag gctcctagag aggggctaca agcaaccggt cctcctacta caccctctgg 1440
gcggtcggac caaggatgac gatgtgcctc tagactggcg gatgaagcag cacgcggctg 1500
tgctcgagga aggggtcctg gatcccaagt caaccattgt tgccatcttt cgtctccca 1560
tgttatatgc tggcccccaca gaggtccagt ggcactgcag gtcccggatg attgcgggtg 1620
ccaatttcta catttgtggg agggaccctg cagggaatgcc ccatcctgaa accaagaagg 1680
atctgtatga acccactcat gggggcaagg tcttgagcat ggcccctggc ctcacctctg 1740
tggaaatcat tccattccga gtggctgcct acaacaaagc caaaaaagcc atggacttct 1800
atgatccagc aaggcacaaat gagtttgact tcatctcagg aactcgaatg aggaagctcg 1860
cccgggaagg agagaatccc ccagatggct tcatggcccc caaagcatgg aaggtcctga 1920
cagattatta caggtccctg gagaagaact aagccttttg ctccagagtt tctttctgaa 1980
gtgctctttg attacctttt ctatttttat gattagatgc tttgtattaa attgcttctc 2040
aatgatgcat tttaatcttt tataatgaag taaaagtgtg gtctataatt aaaaaaaaaat 2100
atatatatat acacacacac atatacatat aaagtcaaac tgaagaccaa atcttagcag 2160
gtaaaagcaa tattcttata catttcataa taaaattagc tctatgtatt ttctactgca 2220
cctgagcagg caggctcccag atttcttaag gctttgtttg accatgtgtc tagttacttg 2280
ctgaaaagtg aatatatttt ccagcatgtc ttgacaacct gtactcttcc aatgtcattt 2340
atcagttgta aaatatatca gattgtgtcc tcttctgtac aattgacaaa aaaaaaaaaat 2400
tttttttctc actctaaaag aggtgtggct cacatcaaga ttcttctgta tattttacct 2460
catgctgtac aaagccttaa tgttgaatc atatcctacg tgttgaagac ctgactggag 2520
aaacaaaatg tggcataacg tgaattttat cttagggatc tgtgcagcct atttctgtca 2580
caaaggtaaa ttgtccaata agggagtctt aatgggc 2617

```

<210> 22

<211> 1130

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1784742CB1

<400> 22

```

ggcggcgacg gcgacggcgg cggcatggcg gagagcgagg ccgagacccc cagcaccocg 60
ggggagttcg agagcaagta cttcgagttc catggcgtgc ggctgccgcc cttctgcgc 120
gggaagatgg aggagatcgc caacttcccg gtgcggccca gcgacgtgtg gatcgtcacc 180
taccccaagt ccggcaccag cttgctgcag gaggtggtct acttggtgag ccagggcgct 240
gaccccgatg agatcggtt gatgaacatc gacgagcagc tcccggctct ggagtaccca 300
cagccgggcc tggacatcat caagggaactg acctctcccc gctcatcaa gagccacctg 360

```

```

ccctaccgct ttctgccctc tgacctccac aatggagact ccaagggtcat ctatatggct 420
cgcaacccca aggatctggt ggtgtcttat tatcagttcc accgctctct gcggaccatg 480
agctaccgag gcacctttca agaattctgc cggaggttta tgaatgataa gctgggctac 540
ggctcctggt ttgagcacgt gcaggagttc tgggagcacc gcatggactc gaacgtgctt 600
tttctcaagt atgaagacat gcatcgggac ctggtgacga tgggtggagca gctggccaga 660
ttcctggggg tgtcctgtga caaggcccag ctggaagccc tgacggagca ctgccaccag 720
ctggtggacc agtgetgcaa cgctgaggcc ctgcccgtgg gccggggaag agttgggctg 780
tggaaggaca tcttcaccgt ctccatgaat gagaagtttg acttgggtga taaacagaag 840
atgggaaagt gtgacctcac gtttgacttt tatttataat aacagaaaca acaacctgca 900
tgctcacaat acccagacag tctactagcc aaaagtcctg tatgcattca tttattcctt 960
gctggacaaa ctctggaagc agcgtgtgaa acagcggggg aagggaagag cggcgtgatc 1020
ggagggagtg tgatgattcc caaccgaaag cagctgtctc gcctttagaa cgtgcagcct 1080
ctccatgtct gattacaaac agtctccaca ttgcagttcc aatgggctgg 1130

```

<210> 23

<211> 872

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1967138CB1

<400> 23

```

gttcccaggc ctcccagtg gttcccagat ggcagacttc tgcgttatga cccggctgct 60
gggctacgtg gaccccctgg atcccagctt tgtggctgcc gtcatcacca tcaccttcaa 120
tccgctctac tggaatgtgg ttgcacgatg ggaacacaag acccgcaagc tgagcagggc 180
cttcggatcc ccctacctgg cctgctactc tctaagcgtc accatcctgc tctgaactt 240
cctgcgctcg cactgcttca cgcaggccat gctgagccag cccaggatgg agagcctgga 300
cacccccgcg gcttacagcc tgggcctcgc gctcctggga ctgggcgtcg tgctcgtgct 360
ctccagcttc tttgcactgg ggttcgctgg aactttccta ggtgattact tcgggatcct 420
caaggaggcg agagtgaccg tgttccccct caacatcctg gacaaccca tgtactgggg 480
aagcacagcc aactacctgg gctgggccat catgcacgcc agccccacgg gcctgctcct 540
gacggtgctg gtggccctca cctacatagt ggctctccta tacgaagagc ccttcaccgc 600
tgagatctac cggcagaaag cctccgggtc ccacaagagg agctgattga gctgcaacag 660
ctttgctgaa ggcttgccca gcctcctggc ctgcccgaag tggcaggccc tgcgaggggc 720
gagaatggtg cctgctgctc agggctcgcc cccggcgtgg gctgccccag tgccttgga 780
cctgctgcct tggggaccct ggacgtgccc acatatggcc attgagctcc aaccacaca 840
ttcccattca ccaataaagg caccctgacc cc 872

```

<210> 24

<211> 1552

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2124351CB1

<400> 24

```

ggggtccgct agtcgcgggg cggcgggcgg ggctgcgggc gcgagggtcc cagcaggatg 60
ccccggctct gcaggaagct gaagtgaag gcccggagag ggcccagccc gcccggggca 120
ggatgaccaa ggccccgctg ttccggctgt ggctggtgct ggggtcgggt ttcgatgcc 180
tgctgatcat cgtgtactgg gacagcgag gcgcgcgca cttctacttg cacacgtcct 240
tctctaggcc gcacacgggg ccgcgcgtgc ccacgcccgg gccggacagg gacagggagc 300

```



```

tcacggccga ctccgatgtc gacgagtttc tggacaagtt tctcagtgtc ggcgtgaagc 360
agagcgacct tcccagaaag gagacggagc agccgcctgc gccggggagc atggaggaga 420
gcgtgagagg ctacgactgg tccccgcgcg acgcccggcg cagcccagac cagggcgggc 480
agcaggcgga gcggaggagc gtgctgcggg gcttctgcgc caactccagc ctggccttcc 540
ccaccaagga gcgcgcattc gacgacatcc ccaactcgga gctgagccac ctgatcgtgg 600
acgaccggca cggggccatc tactgctacg tgcccaaggt ggcctgcacc aactggaagc 660
gcgtgatgat cgtgctgagc ggaagcctgc tgcaccgcgg tgcgcctac cgcgaccgcg 720
tgcgcatccc gcgcgagcac gtgcacaacg ccagcgcgca cctgaccttc aacaagtctc 780
ggcgccgcta cgggaagctc tcccgcacc tcatgaaggt caagctcaag aagtacacca 840
agttcctctt cgtgcgcgac cccttcgtgc gcctgatctc cgccttcgcg agcaagtctc 900
agctggagaa cgaggagttc taccgcaagt tcgccgtgcc catgctgcgg ctgtacgcca 960
accacaccag cctgcccgcg tcggcgcgcg aggccttcgg cgctggcctc aaggtgtcct 1020
tcgccaactt catccagtac ctgctggacc cgcacacgga gaagctggcg cccttcaacg 1080
agcactggcg gcaggtgtac cgcctctgcc acccgtgcca gatcgactac gacttcgtgg 1140
ggaagctgga gactctggac gaggacggcg cgcagctgct gcagctactc caggtggacc 1200
ggcagctccg cttccccccg agctaccgga acaggaccgc cagcagctgg gaggaggact 1260
ggttcgcaa gatccccctg gcctggaggc agcagctgta taaactctac gaggccgact 1320
ttgttctctt cggctacccc aagccgaaa acctctccg agactgaaag ctttcgcgtt 1380
gctttttctc gcgtgcctgg aacctgacgc acgcgcactc cagttttttt atgacctacg 1440
atattgcaat ctgggcttct tgttcaactc actgcctcta tccattgagt actgtatcga 1500
tattgttttt taagattaat atatttcagg tatttaatac gaaaaaaaaa aa 1552

```

<210> 25

<211> 2731

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2153162CB1

<400> 25

```

gccgcaagcg gcatggagga ggcggaggcc gcggcgagcc gggccgagca gtgagggccc 60
tagcgggggc cgagcggggc ccggggcccc taagccattc ctgaagtcac gggctggcca 120
ggacattggt gacccgcaa tccggtatgg acgactggaa gccagcccc ctcatcaagc 180
cctttggggc tcggaagaag cggagctggg accttacctg gaagtataaa ctgacaaacc 240
agcgggcccct gcggagattc tgtcagacag gggcgcgtgt tttcctgctg gtgactgtca 300
ttgtcaatat caagttgac ctggacactc ggcgagccat cagtgaagcc aatgaagacc 360
cagagccaga gcaagactat gatgaggccc taggcgcct ggagcccca cggcgagag 420
gcagtgttcc ccggcgggtc ctggacgtag aggtgtattc aagtcgcagc aaagtatatg 480
tggcagtgga tggcaccacg gtgctggagg atgaggcccg ggagcagggc cggggcatcc 540
atgtcattgt cctcaaccag gccacggggc acgtgatggc aaaacgtgtg tttgacacgt 600
actcacctca tgaggatgag gccatgggtc tattcctcaa catggtagcg cccggccgag 660
tgctcatctg cactgtcaag gatgagggt ccttcacact caaggacaca gccaaaggctc 720
tgctgaggag cctgggcagc caggctggcc ctgccctggg ctggagggac acatgggcct 780
tcgtgggacg aaaaggaggt cctgtcttcg gggagaaaca ttctaagtca cctgccctct 840
cttctggggg ggaccagtc ctgctgaaga cagatgtgcc attgagctca gcagaagagg 900
cagagtgcc ctgggcagac acagagctga accgtcgccg ccggcgcttc tgcagcaaag 960
ttgagggcta tggaagtgtg tgacgtgca aggacccac acccatcgag ttcagccctg 1020
accactccc agacaacaag gtctcaatg tgctgtggc tgtcattgca gggaaaccgc 1080
ccaattacct gtacaggatg ctgcgctctc tgctttcagc ccagggggtg tctcctcaga 1140
tgataacagt tttcattgac ggctactat aggaacccat ggatgtgggt gcaactgttt 1200
gtctgagggg catccagcat actcccatca gcatcaagaa tgcccgctg tctcagcact 1260
acaaggccag cctcactgcc actttcaacc tgtttccgga ggccaagttt gctgtggttc 1320
tggaagagga cctggacatt gctgtggatt ttttcagttt cctgagccaa tccatccacc 1380
tactggagga ggatgacagc ctgtactgca tctctgcctg gaatgaccag gggatgaac 1440

```

```

acacggctga ggaccagca ctactgtacc gtgtggagac catgcctggg ctgggctggg 1500
tgctcaggag gtccttgtac aaggaggagc ttgagcccaa gtggcctaca ccggaaggc 1560
tctgggattg ggacatgtgg atgcggatgc ctgaacaacg ccggggccga gaggatcatca 1620
tccctgacgt ttcccgatcc taccactttg gcatcgtegg cctcaacatg aatggctact 1680
ttcacgaggc ctacttcaag aagcacaagt tcaacacggg tccagggtgtc cagctcagga 1740
atgtggacag tctgaagaaa gaagcttatg aagtggaggt tcacaggctg ctcatgagg 1800
ctgagggttct ggaccacagc aagaaccctt gtgaagactc ttctctgcca gacacagagg 1860
gccacaccta cgtggccttt attcgaatgg agaaagatga tgacttcacc acctggaccc 1920
agcttgccaa gtgcctccat atctgggacc tggatgtgcg tggcaaccat cggggcctgt 1980
ggagattgtt tcggaagaag aaccacttcc tgggtggggg ggtcccggct tccccctact 2040
cagtgaagaa gccaccctca gtcaccccaa ttttcttggg gccaccccca aaggaggagg 2100
gagccccagg agccccagaa cagacatgag acctcctcca ggaccctgcg gggctgggta 2160
ctgtgtaccc ccaggctggc tagcccttcc ctccatcctg taggattttg tagatgctgg 2220
taggggctgg ggctacctg ttttaacat gagacttaat tactaactcc aaggggaggg 2280
ttccccctgt ccaacacccc gttctgagt taaaagtcta tttatttact tccttggttg 2340
agaagggcag gagagtacct gggaatcatt acgatcccta gcagctcatc ctgccctttg 2400
aataccctca ctttcaggc ctggctcaga atctaacctt tttattgact gtccctgaggg 2460
ccttgaaaac aggcggaacc tggagggcct ggatttcttt ttgggctgga atgctgcct 2520
gaggggtggg ctggctctta ctcaggaaac tgctgtgccc aacccatgga caggccagc 2580
tgggggccac atgctgacac agactcactc agagaccctt agacactgga ccaggcctcc 2640
tctcagcctt ctctttgtcc agatttccaa agctggataa gttggctcatt gattaaaaa 2700
ggagaagccc tctgggaaaa aaaaaaaaaa a 2731

```

<210> 26

<211> 2065

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2617407CB1

<400> 26

```

gccaggatgc ctccagtctg ggggaaaatg cttcctcatt tgcttctccc agcccacctc 60
aagcagtctc cccacccctt gagtctcagc agtggttaaag ctgttacttt cacagcttcc 120
tgggagcgag tgctttctca agcccgctct gcaagggtctt ccacttcagc acaatgttac 180
tgccataaaa aatgaagctc ctgctgtttc tgggtttcca gatggccatc ttggctctat 240
tcttccacat gtacagccac aacatcagct cctgtctat gaaggcacag cccgagcgca 300
tgacgtgct ggttctgtct tcctggcgct ctggctcttc tttgtgggg cagctttttg 360
ggcagcacc agatgttttc tacctgatgg agcccgctg gcacgtgtgg atgaccttca 420
agcagagcac cgcctggatg ctgcacatgg ctgtgcggga tctgatacgg gccgtcttct 480
tgtgcgacat gagcgtcttt gatgcctaca tggaaacctg tccccggaga cagtccagcc 540
tctttcagtg ggagaacagc cgggcccgtg gttctgcacc tgccgtgtgac atcatccac 600
aagatgaatc atccccggg ctactgcag gctcctgtgc agtcaacagc cctttgaagt 660
tggtggagaa agcctgccgc tcctacagcc acgtggtgct caaggagggt cgcttcttca 720
acctgcagtc cctctaccgc ctgctgaaag acccctccct caacctgcat atcgtgcacc 780
tggtcgggga cccccgggcc gtgttcggtt cccgagaacg cacaaaggga gatctcatga 840
ttgacagtgc cattgtgatg gggcagcatg agcagaaact caagaaggag gaccaaccct 900
actatgtgat gcaggctatc tgccaaagcc agctggagat ctacaagacc atccagtcct 960
tgcccaaggc cctgcaggaa cgctacctgc ttgtgcgcta tgaggacctg gctcgagccc 1020
ctgtggccca gacttcccga atgtatgaat tcgtgggatt ggaattcttg ccccatcttc 1080
agacctgggt gcataacatc acccgaggca agggcatggg tgaccacgct ttccacacaa 1140
atgccaggga tgcccttaat gtctccagc cttggcgctg gtctttgccc tatgaaaagg 1200
tttctcgact tcagaaagcc tgtggcgatg ccatgaattt gctgggctac cgccacgtca 1260
gatctgaaca agaacagaga aacctgttgc tggatcttct gtctacctg actgtccctg 1320
agcaaatcca ctaagagggt tgagaaggct ttgctgccac ctggtgtcac cctcagtcac 1380

```

```

tttctctgaa tgcttctgag ccttgccctac atctctgagc cttactactaca tgtctgtggg 1440
tatcacactg agtgtgagtt gtgtccacac gtgtcgaagc agaaggactt ttgtgtccat 1500
gcttgtgtct agaaaacaga ctggggaacc ttatgtgagc agcacatccc accagtgaag 1560
cagggtattg ctcttcttct tttcttgatc ttctgtctg ggcagacttc agagactttg 1620
tggcctggag gcctattaag cacgacacag tatcagtga attgatccat aaacctccct 1680
gtccacatct tgcccaatgg ggaatggatc tttcaccaa gagctacca gcattttcca 1740
cagagatgca aattctgagc ccttgaggat cccagtggat tcaaggaagg aagtgggaac 1800
aagggtggat gcctacttat gagcttgacc atcacagcta tcggtaatca gaaatatgaa 1860
acaaaatctc tgcacaaaag agcaagctct taagttcaca ggggtgcctg gctgcatttg 1920
aatatcactt cccctctgca ttttccatc acatagaaga ctttgacctg tgaagctgcc 1980
atctgttaat actaaaattc ccaataaagg ttctgtttag aatgtccctt tttatgcttc 2040
ttaattatta gcagtaaatg ttcatt 2065

```

<210> 27

<211> 2748

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2963717CB1

<400> 27

```

cgagagacag gaatcgggggt ttctgggtga cggatgatctc ggggtgggca ggactccaaa 60
ggcccgtcga cccggtgggt gactccttgc actgggattg gacatatgca agcgggagat 120
ttggggcccg cgctcaaaat cggggggcgg ggggtggactc gggtttgga cccaggatcc 180
gatcagcgga cccttgattc aacgtgggct ccagcgtgac atggctgaag cgcaccaggc 240
cgtgggcttc cgaccctcgc tgacctcgga cggggctgaa gtggaactca gtgcccctgt 300
gctgcaggag atctacctct ctggcctgcg ctccctggaaa aggcactctc cacgtttctg 360
gaatgacttt ctaccgggtg tgtttctgc cagccccctc agttggcttt tctcttctag 420
tgccatccag ctgctctggt tctccagct ggatccttcc ttaggactga tggagaagat 480
caaagagttg ctgcttgact ggggtggaca acaccacggg ctccgggggg tcttggcagc 540
cgcgctggtt gcctcggtt tggtggggagc cctgatcttc aactgcacg tggccctgag 600
gctgcttctg tctaccacg gctggcttct tgagccccac ggagccatgt cctccccac 660
caagacctgg ctggccctgg tccgcatctt ctctggcgc caccgatgc tgttcagtta 720
ccagcgctcc ctgccacgcc agcccggtgc ctctgtgcag gacaccgtgc gcaagtaact 780
ggagtcggtc cggcccatcc tctccgacga ggacttcgac tggaccggcg tcttggcgca 840
ggaattctct aggtgcagg cgtcactgct gcagtggtag ctgcggctca agtctgggtg 900
ggcgtccaat tatgtcagtg actgggtggga ggaatttggt tacctgcgct cccgaaatcc 960
gctgatggtg aacagcaact attacatgat ggacttctct tatgtcacac ccacgcctct 1020
gcaggcagct cgcgctggga atgcggtcca tgccctctct ctgtaccgcc accgcctgaa 1080
ccgcccaggag atacccccga ctttgctgat gggaatgctc cccttatgct ctgcccagta 1140
cgagaagatc ttcaacacca cgcggattcc aggggtccaa aaagactaca tccgccacct 1200
ccatgacagc caacacgtgg ctgtcttcca cgggggcga ttcttccgca tggggaccca 1260
ctccccaaac agcctgcttt ccccgagagc cctggagcag cagtttcaga gaatcctgga 1320
tgatccctca cggcctgcc cccacgagga acatctggca gctctgacag ctgctcccag 1380
gggcacgtgg gccaggtgc ggacatccct gaagaccag gcagcggagg cctggaggc 1440
ggtggaagg ggcgctttct ttgtgtcact ggatgctgag cccgcggggc tcaccaggga 1500
ggaccgggca gcgtcgttg atgcctacgc ccattgctct ctggctgggc ggggccatga 1560
tcgctggttt gacaaatcct tcacctaat cgtcttctct aacgggaagc tgggcctcag 1620
cgtggagcac tctggggcg actgccccat ctccaggcac atgtgggagt tcaactctggc 1680
tacagaatgc tttcagctgg gctactcaac agatggccac tgcaaggggc acccggaacc 1740
cacactacc cagccccagc ggctgcaatg ggaccttcca gaccgatcc actcctccat 1800
ctctctagcc ctgaggggag ccaagatctt gctgaaaaat gtcgactgcc atgtcgttcc 1860
attctcccta tttggcaaga gcttcatccg acgctgccac ctctcttctg acagcttcat 1920
ccagatcgcc ttgcaactgg cccacttccg ggacaggggt caattctgcc tgacttatga 1980

```

```

gtcggccatg actcgttat tcctggaagg ccggacggag acggtgcggt cttgcacgag 2040
ggaggcctgc aactttgtca gggccatgga ggacaaagag aagacggacc cacagtgcct 2100
cgccctgttc cgcgtggcag tggacaagca ccaggctctg ctgaaggcag ccatgagcgg 2160
gcaggagtt gaccgccacc tgtttgcgct gtacategtg tcccgattcc tccacctgca 2220
gtcgcccttc ctgaccaggg tccattcgga gcagtggcag ctgtccacca gccagatccc 2280
tgttcagcaa atgcactgtg ttgacgtcca caattaccg gactatgttt cctcaggcgg 2340
tggattcggg cctgctgatg accatgggta tgggtgttct tatacttca tgggggatgg 2400
catgatcacc ttccacatct ccagcaaaaa atcaagcaca aaaacggatt cccacaggct 2460
ggggcagcac attgaggacg cactgctgga tgtggcctcc ctgttccagg cgggacagca 2520
ttttaagcgc cggttcagag ggtcagggaa ggagaactcc aggcacagggt gtggatttct 2580
ctcccgcag actggggcct ccaaggcctc aatgacatcc accgacttct gactccttcc 2640
agcaggcagc tggcctctcc aaggaataag ggtgaaattg ccacagctgg ctgacacagg 2700
acaggggcaa ctgggttggc aacccacat ccaggcaaat aaagatgg 2748

```

<210> 28

<211> 1079

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3360857CB1

<400> 28

```

caggatggtg gacagcgtgt accggacccg ctccctgggg gtggcgccg aagggtccc 60
ggaccagtac gcggaagggg aggcggcgcg cgtgtggcag ctgtatatcg gagacacccg 120
cagccgcacc gccgagtaca aggcattggt gcttgggctg ctgcgccagc acggctgcca 180
gcgggtgctc gacgtagcct gtggcactgg ggtggactcc attatgctgg tggaaagagg 240
cttcagtgtg acgagtgtgg atgccagtga caagatgctg aagtatgac ttaaggagcg 300
ctggaaccgg cggcacgagc ccgccttcga caagtgggtc atcgaagaag ccaactggat 360
gactctggac aaagatgtgc ccagtcagc agagggtggc tttgatgctg tcatctgcct 420
tggaaacagt ttcgctcact tgccagactg caaaggggac cagagtgagc accggctggc 480
gctgaaaaac attgcgagca tggtgcgggc agggggccta ctggtcattg atcatcgcaa 540
ctacgaccac atcctcagta caggctgtgc acccccaggg aagaacatct actataagag 600
tgacttgacc aaggacgtca caacatcagt gctgatagtg aacaacaagg cccacatggt 660
gaccctggac tatacgtgac aggtgccggg ggctggccag gatggctctc ctggcttgag 720
taagtccgg ctctcctact acccactctg tctggcatcc ttcacggagc tgctccaagc 780
agccttcgga ggtaagtgc agcacagcgt cctggcgac ttcaagcctt acaagccagg 840
ccaaacctac attcctctgt acttcatcca cgtgctcaag aggacagact gagtgtggcc 900
tcagctcca caagcctctg ccagggcact gctaggctct gtctggaaga tggggaccag 960
cagccccaca ccaggccag cctctagagc agactacagc tggggtgcag ggatgtgggt 1020
tccacagacg gaagggtaaa caatatagtc tttttcagtt cctgcaaaaa aaaaaaaaaa 1079

```

<210> 29

<211> 2340

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3449671CB1

<400> 29

```

gcgcacgctt cggggtctcc gggaagtgc ggcccttcg gatgtggcg atgcggcgt 60
gagccggcgg gggaggtgct gctgctgcct ccaactgtact cagaccagg tagcacagga 120

```

```

ttgtccatcc tccagcagct cagtgcacag gtgtgaactc agcctgtttc agagcctcca 180
caccatgacc tccaagaagc tgggtgaactc ggtggctggc tgtgctgatg acgctcttgc 240
tggcctgggt gcctgcaacc ccaacctgca gctcctgcag ggccaccgcg tggccctccg 300
ttctgacctg gacagcctca agggccgggt ggcaactgctg tcgggtgggg gctctggcca 360
tgagcctgcc catgctggtt tcatagggaa ggggatgctg actgggggtca tcgcgggagc 420
tgtgttcacc tccccggcag tgggcagcat cctggcagcc atcagggccg tggcccaggc 480
cggcacagtg gggacgctcc ttatcgtgaa gaactacact ggggatcggc tcaacttcgg 540
cctggcccgg gagcaggccc gggctgaagg catcccgggt gagatgggtg tgattgggga 600
cgacagcgcc ttcactgtcc tgaagaaggc aggcggcggt gggctgtgct gcaccgtgct 660
tatacacaag gtggcaggtg ctctggctga ggctgggtg gggctggagg agatcgcaaa 720
gcaggtgaac gtggtcacca aggccatggg taccctgggg gtgagcttat cctcctgcag 780
cgtccctgggt tccaaaccca ccttcgagct ctacgcccag gaggtggagc tgggctgggg 840
gatccacggg gaagctgggt tgcgcgggat aaagatggca accgcccgat agattgtgaa 900
actcatgtct gaccacatga caaacaccac caacgcgtcc catgtgcctg tgcagcccgg 960
ctcctcagtt gtgatgatgg tcaacaacct ggggtggcctg tcattcctgg aactgggcat 1020
catagccgac gctaccgtcc gctccctgga gggccgcggt gtgaagattg cccgtgcctt 1080
ggtgggcacc ttcattgtcag cactggagat gcctggcatt tctctcacc tcctgctggg 1140
ggatgagcct ctccctgaaac tgatagatgc tgaaccact gcagcagcct ggcctaactg 1200
ggctgcagtc tccattactg ggcggaagcg gagccgggta gcccctgccg agccccagga 1260
ggccccctgat tccactgctg caggaggtc agcctcgaag cggatggcgc tgggtgctgga 1320
acgggtgtgc agcactctcc tgggcctgga ggaacacctg aatgccctgg accgggctgc 1380
tgggtgacggc gactgtggca ccaccacag ccgtgcggcc agagcaatcc aggagtggct 1440
gaaggagggc ccaccctctg ccagccctgc ccagctgctc tccaagttgt ctgttctgct 1500
cctggagaag atgggaggct catctggggc gctctatggc ctgttctctga ctgcggtgct 1560
acagcccctg aaggccaaga ccagcctccc agcctgggtc gctgccatgg atgccggcct 1620
ggaagccatg cagaagtatg gcaaggctgc tccaggggac aggactatgc tggattctct 1680
gtgggcagcg gggcaggagc tccaagcctg gaagagccca ggagctgatc tgttacaagt 1740
cctgacccaa gcagtcaga gtgcgaagc tgcagccgag gccaccaaga atatggaagc 1800
tggagccgga agagccagtt atatcagctc agcacggctg gagcagccag accccggggc 1860
ggtggcagct gctgccatcc tccgggcatc cttggagggtc ttgcagagct aggggtgtgtg 1920
actgcctccc ttggcctcag ctctctcac tgcgtgctg aggtggcctt tgtcacttcc 1980
ttctgccttc caaccctcac ctcccccggt cctggcccca ttggccacc ctctaagttg 2040
agcaggaaat cctccaccaa gcttcagaa ctacagacag caccagagt gagctggagt 2100
gggtcccatc gcctctccag catgccctt ccctttgcag gaggggtggag tccctgggtc 2160
atgccctccc ctgccagctc tgggcttcag agataaggca ttttcttgt gcagccttta 2220
cctggcaatc ctaatttgggt tttaagactc cctgtgaaat gctttccgca ccttaacccc 2280
agtgagcgtg aaaaagaaag ttaataaact ataatacatg gaagcaagaa aaaaaaaaaa 2340

```

<210> 30

<211> 821

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5497787CB1

<400> 30

```

gccgtcgccg ccatttcaag accgtactag gtagatgggtc aattagagtt cccagggttt 60
gaagcctgta actgctgcg ccgctcaagc cctccagagc attgctacgg ctgctgcctt 120
tgtactacta cctccaaata cgttcttgct ggtagtggcg gcagcaggac caattacctc 180
ttttttgtct tccctcgaga agctccagat ggcgtcttcc gtgggcaacg tggccgacag 240
cacagaacca acgaaacgta tgctttcctt ccaagggtta gctgagttgg cacatcgaga 300
atatcaggca ggagattttg aggcagctga gagacactgc atgcagctct ggagacaaga 360
gccagacaat actggtgtgc ttttattact ttcatctata cacttccagt gtcgaaggct 420
ggacagatct gctcacttta gcactctggc aattaaacag aaccccttcc tggcagaagc 480

```

```

ttattcgaat ttggggaatg tgtacaagga aagagggcag ttgcaggagg caattgagca 540
ttatcgacat gcattgcgtc tcaaacctga ttcatcgat gggtatatta acctggcagc 600
cgccttggtg gcagcgggtg acatggaagg ggcagtacaa gcttacgtct ctgctcttca 660
gtacaatcct gatttggtact gtgttcgcag tgacctgggg aacctgctca aagccctggg 720
tcgcttggaag gaagccaagg taggtgtttg atagaacaca tttaaaccatc agtattatga 780
aaacttgtag tttttgccaa gtcttcaact cttcattgag c 821

```

<210> 31

<211> 478

<212> PRT

<213> Homo sapiens

<300>

<308> g2443814

<400> 31

```

Met Met Glu Gly Asn Gly Asn Gly His Glu His Cys Ser Asp Cys
1          5          10          15
Glu Asn Glu Glu Asp Asn Ser Tyr Asn Arg Gly Gly Leu Ser Pro
20          25          30
Ala Asn Asp Thr Gly Ala Lys Lys Lys Lys Lys Gln Lys Lys
35          40          45
Lys Lys Glu Lys Gly Ser Glu Thr Asp Ser Ala Gln Asp Gln Pro
50          55          60
Val Lys Met Asn Ser Leu Pro Ala Glu Arg Ile Gln Glu Ile Gln
65          70          75
Lys Ala Ile Glu Leu Phe Ser Val Gly Gln Gly Pro Ala Lys Thr
80          85          90
Met Glu Glu Ala Ser Lys Arg Ser Tyr Gln Phe Trp Asp Thr Gln
95          100         105
Pro Val Pro Lys Leu Gly Glu Val Val Asn Thr His Gly Pro Val
110         115         120
Glu Pro Asp Lys Asp Asn Ile Arg Gln Glu Pro Tyr Thr Leu Pro
125         130         135
Gln Gly Phe Thr Trp Asp Ala Leu Asp Leu Gly Asp Arg Gly Val
140         145         150
Leu Lys Glu Leu Tyr Thr Leu Leu Asn Glu Asn Tyr Val Glu Asp
155         160         165
Asp Asp Asn Met Phe Arg Phe Asp Tyr Ser Pro Glu Phe Leu Leu
170         175         180
Trp Ala Leu Arg Pro Pro Gly Trp Leu Pro Gln Trp His Cys Gly
185         190         195
Val Arg Val Val Ser Ser Arg Lys Leu Val Gly Phe Ile Ser Ala
200         205         210
Ile Pro Ala Asn Ile His Ile Tyr Asp Thr Glu Lys Lys Met Val
215         220         225
Glu Ile Asn Phe Leu Cys Val His Lys Lys Leu Arg Ser Lys Arg
230         235         240
Val Ala Pro Val Leu Ile Arg Glu Ile Thr Arg Arg Val His Leu
245         250         255
Glu Gly Ile Phe Gln Ala Val Tyr Thr Ala Gly Val Val Leu Pro
260         265         270
Lys Pro Val Gly Thr Cys Arg Tyr Trp His Arg Ser Leu Asn Pro
275         280         285
Arg Lys Leu Ile Glu Val Lys Phe Ser His Leu Ser Arg Asn Met
290         295         300

```

```

Thr Met Gln Arg Thr Met Lys Leu Tyr Arg Leu Pro Glu Thr Pro
305 310 315
Lys Thr Ala Gly Leu Arg Pro Met Glu Thr Lys Asp Ile Pro Val
320 325 330
Val His Gln Leu Leu Thr Arg Tyr Leu Lys Gln Phe His Leu Thr
335 340 345
Pro Val Met Ser Gln Glu Glu Val Glu His Trp Phe Tyr Pro Gln
350 355 360
Glu Asn Ile Ile Asp Thr Phe Val Val Glu Asn Ala Asn Gly Glu
365 370 375
Val Thr Asp Phe Leu Ser Phe Tyr Thr Leu Pro Ser Thr Ile Met
380 385 390
Asn His Pro Thr His Lys Ser Leu Lys Ala Ala Tyr Ser Phe Tyr
395 400 405
Asn Val His Thr Gln Thr Pro Leu Leu Asp Leu Met Ser Asp Ala
410 415 420
Leu Val Leu Ala Lys Met Lys Gly Phe Asp Val Phe Asn Ala Leu
425 430 435
Asp Leu Met Glu Asn Lys Thr Phe Leu Glu Lys Leu Lys Phe Gly
440 445 450
Ile Gly Asp Gly Asn Leu Gln Tyr Tyr Leu Tyr Asn Trp Lys Cys
455 460 465
Pro Ser Met Gly Ala Glu Lys Val Gly Leu Val Leu Gln
470 475

```

<210> 32

<211> 361

<212> PRT

<213> Arabidopsis thaliana

<300>

<308> g2642159

<400> 32

```

Met Lys Ala Leu Ile Leu Val Gly Gly Phe Gly Thr Arg Leu Arg
1 5 10 15
Pro Leu Thr Leu Ser Phe Pro Lys Pro Leu Val Asp Phe Ala Asn
20 25 30
Lys Pro Met Ile Leu His Gln Ile Glu Ala Leu Lys Ala Val Gly
35 40 45
Val Asp Glu Val Val Leu Ala Ile Asn Tyr Gln Pro Glu Val Met
50 55 60
Leu Asn Phe Leu Lys Asp Phe Glu Thr Lys Leu Glu Ile Lys Ile
65 70 75
Thr Cys Ser Gln Glu Thr Glu Pro Leu Gly Thr Ala Gly Pro Leu
80 85 90
Ala Leu Ala Arg Asp Lys Leu Leu Asp Gly Ser Gly Glu Pro Phe
95 100 105
Phe Val Leu Asn Ser Asp Val Ile Ser Glu Tyr Pro Leu Lys Glu
110 115 120
Met Leu Glu Phe His Lys Ser His Gly Gly Glu Ala Ser Ile Met
125 130 135
Val Thr Lys Val Asp Glu Pro Ser Lys Tyr Gly Val Val Val Met
140 145 150
Glu Glu Ser Thr Gly Arg Val Glu Lys Phe Val Glu Lys Pro Lys

```

155	160	165
Leu Tyr Val Gly	Asn Lys Ile Asn Ala Gly	Ile Tyr Leu Leu Asn
170	175	180
Pro Ser Val Leu	Asp Lys Ile Glu Leu Arg	Pro Thr Ser Ile Glu
185	190	195
Lys Glu Thr Phe	Pro Lys Ile Ala Ala Ala	Gln Gly Leu Tyr Ala
200	205	210
Met Val Leu Pro	Gly Phe Trp Met Asp	Ile Gly Gln Pro Arg Asp
215	220	225
Tyr Ile Thr Gly	Leu Arg Leu Tyr Leu Asp	Ser Leu Arg Lys Lys
230	235	240
Ser Pro Ala Lys	Leu Thr Ser Gly Pro His	Ile Val Gly Asn Val
245	250	255
Leu Val Asp Glu	Thr Ala Thr Ile Gly Glu	Gly Cys Leu Ile Gly
260	265	270
Pro Asp Val Ala	Ile Gly Pro Gly Cys Ile	Val Glu Ser Gly Val
275	280	285
Arg Leu Ser Arg	Cys Thr Val Met Arg Gly	Val Arg Ile Lys Lys
290	295	300
His Ala Cys Ile	Ser Ser Ser Ile Ile Gly	Trp His Ser Thr Val
305	310	315
Gly Gln Trp Ala	Arg Ile Glu Asn Met Thr	Ile Leu Gly Glu Asp
320	325	330
Val His Val Ser	Asp Glu Ile Tyr Ser Asn	Gly Gly Val Val Leu
335	340	345
Pro His Lys Glu	Ile Lys Ser Asn Ile Leu	Lys Pro Glu Ile Val
350	355	360
Met		

<210> 33

<211> 373

<212> PRT

<213> Caenorhabditis elegans

<300>

<308> g2804432

<400> 33

Met Val Val Ser	Pro Leu Pro Ser Met	Lys Ala Leu Ile Leu Val
1	5	10
Gly Gly Tyr Gly	Thr Arg Leu Arg Pro	Leu Thr Leu Thr Gln Pro
20	25	30
Lys Pro Leu Val	Glu Phe Ala Asn Lys	Pro Met Met Leu His Gln
35	40	45
Met Glu Ala Leu	Ala Glu Val Gly Val	Asp Thr Val Val Leu Ala
50	55	60
Val Ser Tyr Arg	Ala Glu Gln Leu Glu	Gln Glu Met Thr Val His
65	70	75
Ala Asp Arg Leu	Gly Val Lys Leu Ile	Phe Ser Leu Glu Glu Glu
80	85	90
Pro Leu Gly Thr	Ala Gly Pro Leu Ala	Leu Ala Arg Lys His Leu
95	100	105
Glu Gly Asp Ala	Pro Phe Phe Val Leu	Asn Ser Asp Val Ile Cys
110	115	120
Asp Phe Pro Phe	Lys Gln Met Val Glu	Phe His Lys Asn His Gly

	125		130		135
Lys Glu Gly Thr	Ile Ala Val Thr Lys	Val Glu Glu Pro Ser Lys			
	140		145		150
Tyr Gly Val Val	Val Phe Asp Gln Asp	Lys Gly Lys Ile Asp Asp			
	155		160		165
Phe Val Glu Lys	Pro Gln Glu Tyr Val	Gly Asn Lys Ile Asn Ala			
	170		175		180
Gly Leu Tyr Ile	Phe Ser Ser Lys Ile	Leu Asp Arg Ile Pro Leu			
	185		190		195
Lys Pro Thr Ser	Ile Glu Lys Glu Ile	Phe Pro Glu Met Ala Phe			
	200		205		210
Ser Gly Asn Leu	Tyr Ala Phe Val Leu	Pro Gly Phe Trp Met Asp			
	215		220		225
Val Gly Gln Pro	Lys Asp Phe Leu Lys	Gly Met Ser Leu Phe Leu			
	230		235		240
Asn His Cys His	Thr Thr Lys Ser Asp	Lys Leu Glu Thr Gly Ser			
	245		250		255
Asn Ile His Pro	Thr Ala Thr Ile Arg	Gly Asn Val Met Val Asp			
	260		265		270
Pro Ser Ala Thr	Val Gly Glu Asn Cys	Val Ile Gly Pro Asp Val			
	275		280		285
Val Ile Gly Pro	Arg Val Lys Ile Glu	Gly Gly Val Arg Ile Leu			
	290		295		300
His Ser Thr Ile	Leu Ser Asp Ser Ser	Ile Gly Asn Tyr Ser Trp			
	305		310		315
Val Ser Gly Ser	Ile Val Gly Arg Lys	Cys His Ile Gly Ser Trp			
	320		325		330
Val Arg Ile Glu	Asn Ile Cys Val Ile	Gly Asp Asp Val Val Val			
	335		340		345
Lys Asp Glu Leu	Tyr Leu Asn Gly Ala	Ser Val Leu Pro His Lys			
	350		355		360
Ser Ile Ala Val	Asn Val Pro Ser Lys	Asp Ile Ile Met			
	365		370		

THIS PAGE BLANK (USPTO)